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Abstract  
 
Overexpression of the hepatocyte growth factor receptor (c-Met) and its 
ligand, the hepatocyte growth factor (HGF), and a constitutively active mutant of 
the epidermal growth factor receptor (∆EGFR/EGFRvIII), occur frequently in 
glioblastoma.  c-Met is activated in a ligand-dependent manner by HGF or in a 
ligand-independent manner by ∆EGFR. Dysregulated c-Met signaling contributes 
to the aggressive phenotype of glioblastoma, yet the mechanisms underlying the 
production of HGF in glioblastoma are poorly understood. We found a positive 
correlation between HGF and c-Met expression in glioblastoma, suggesting that 
they are coregulated. This is supported by the finding that in a c-Met/HGF axis-
dependent glioblastoma cell line, shRNA-mediated silencing of c-Met, or treatment 
with the c-Met inhibitor SU11274, attenuated HGF expression. Biologically, c-Met 
knockdown decreased anchorage-independent colony formation and the 
tumorigenicity of intracranial xenografts. Building on prior findings that ∆EGFR 
 
 
ix 
 
enhanced c-Met activation, we found that ∆EGFR also led to increased HGF 
expression, which was reversed upon ∆EGFR inhibition with AG1478. ∆EGFR 
required c-Met to maintain elevated HGF expression, colony formation of 
glioblastoma cells, and the tumorigenicity of orthotopic xenografts. An unbiased 
mass spectrometry-based approach identified phosphotyrosine-related signaling 
changes that occurred with c-Met knockdown in a glioblastoma cell line 
expressing ΔEGFR and in parental cells. Notably, phosphorylation of STAT3, a 
master regulator of the mesenchymal GBM subtype and a known target of 
∆EGFR, also decreased when c-Met was silenced in these cells, suggesting that 
the signals from these receptors converge on STAT3. Using a STAT3 inhibitor, 
WP1193, we showed that STAT3 inhibition decreased HGF mRNA expression in 
ΔEGFR-expressing glioblastoma cells. Consistent with these findings, 
constitutively active STAT3 partially restored HGF expression and anchorage-
independent growth of c-Met knockdown glioblastoma cells that overexpressed 
ΔEGFR. We found that higher levels of HGF and c-Met expression associated 
with the mesenchymal GBM subtype. Taken together, these results suggest that 
the activity of c-Met regulates the expression of HGF in glioblastoma cells, that 
∆EGFR feeds positively into this autocrine loop, that signaling of the two receptors 
together modulate HGF expression via STAT3, and that the HGF/c-Met axis may 
therefore be a good additional target for therapy of mesenchymal GBM tumors. 
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Glioma 
 
Gliomas account for the majority of primary brain malignancies found in 
adults (Sathornsumetee et al., 2007).  The main glioma subtypes include 
astrocytomas, oligodendrogliomas, and ependymomas (Yan et al., 2009).  The 
most common group of gliomas are the astrocytomas, and are otherwise known 
as glial tumors (Gonzalez and Gilbert, 2005).  On the basis of pathology and 
clinical criteria, the World Health Organization (WHO) classifies astrocytomas into 
one of four grades; grades I through IV (Yan et al., 2009).  Grade I astrocytic 
tumors may be either pilocytic astrocytomas or subependymal giant cell 
astrocytomas (Louis et al., 2007).  These low-grade lesions are not aggressive, 
are generally benign, and are typically cured by surgical resection (Yan et al., 
2009). Grade II astrocytic tumors include pilomyxoid astrocytomas, diffuse 
astrocytomas, and pleomorphic xanthoastrocytomas, and grade III astrocytic 
tumors are called anaplastic astrocytomas (Louis et al., 2007). Grade II and 
Grade III astrocytic lesions are infiltratively aggressive, may progress to a higher 
grade lesion, and are associated with a poor clinical outcome (Yan et al., 2009).  
Glioblastomas, gliosarcomas, and giant cell glioblastomas are characterized as 
WHO grade IV tumors (Louis et al., 2007). These high grade gliomas are highly 
invasive and are associated with an extremely poor clinical prognosis (Yan et al., 
2009).  The clinical prognosis of glioma patients depends on several criteria, 
amongst them are age of the patient, performance status (Karnofsky Performance 
Scale Score), and grade of the lesion (Görke et al., 2010).  
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Glioblastoma 
 
Glioblastoma (GBM) may arise de novo (primary GBM; represents about 
90% of cases) or from less malignant precursor lesions (secondary GBM) (Ohgaki 
and Kleihues, 2011).  Primary GBM typically affects people that are older than 45 
years of age, while secondary GBM occurs more frequently in individuals that are 
younger than that (Furnari et al, 2007). As our understanding of the molecular 
pathogenesis of GBM has evolved, it has become clearer that primary and 
secondary GBM have very different genetic profiles, even though they appear 
indistinguishable by histology (Ohgaki and Kleihues, 2011). 
Approximately 9000 people in the United States are diagnosed with GBM 
per annum (Reardon and Wen, 2006).  Of all human tumors, GBM is the most 
difficult neoplasm to treat (Chakravarti et al., 2001).  Even with the refinement of 
conventional treatment options for GBM patients, outcomes have only slightly 
improved over the past few decades (Sathornsumetee et al., 2007).  The overall 
five year survival rate for GBM patients is 3.4% (Gonzalez and Gilbert, 2005), with 
most patients succumbing to the disease within 14 months (Görke et al., 2010).   
However, as we understand more about the molecular pathogenesis of GBM, 
targeted therapies will likely revolutionize their treatment (Sathornsumetee et al., 
2007).   
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GBM Treatment 
 
 The current standard of care for newly diagnosed GBM patients is to 
surgically remove as much of the lesion/lesions as possible, followed by 
fractionated radiotherapy along with concurrent and adjuvant treatment with 
temozolomide (TMZ) (Colman, et al., 2010; Stupp et al., 2005). TMZ is a DNA 
alkylating agent that methylates DNA at the O6 position of guanine (Lassman and 
Holland, 2007). This results in several nucleotide mismatches in complementary 
DNA, leading to many unsuccessful post-replicative attempts at mismatch repair, 
ultimately leading to apoptosis (D'Atri et al., 1998). One significant prognostic 
indicator of a favorable response to TMZ treatment is the degree of methylation, 
or epigenetic silencing, of the O6-methylguanine-DNA-methyltransferase (MGMT) 
gene promoter (Colman et al., 2010; Weller et al., 2010). MGMT promoter 
methylation is commonly found (40–57%) in GBM (Ohgaki and Kleihues, 2009). 
MGMT is a DNA repair protein that restores O6-alkylated bases caused by 
chemotherapy, thereby counteracting the effect of TMZ treatment (Krakstad and 
Chekenya, 2010). In a large multi-center phase III trial that evaluated the use of 
TMZ for the treatment of primary GBM with different MGMT promoter methylation 
statuses, improved survival was reported for those patients whose tumors had 
methylation of the MGMT promoter (Sulman and Aldape, 2011).  
Over the past few decades we have only seen a marginal improvement in 
progression-free and overall survival, and therefore pre-clinical researchers have 
focused their attention on being able to understand the genetic pathobiology of 
these tumors (Gonzalez and Gilbert, 2005). Even though targeted 
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chemotherapeutic approaches are still in their infancy, they hold a promise of 
being able to alter the course of this relentless disease (Furnari et al., 2007). 
Currently there are many challenges that hinder the responsiveness of 
GBMs to targeted and non-targeted chemotherapy. One of the major obstacles 
limiting treatment effectiveness is that perhaps not all of the neoplastic cells are 
completely removed during resection, which invariably results in tumor recurrence. 
Additionally, progenitor cells present in the bulk of the tumor are inherently 
resistant to radiotherapy, and go on to form recurrent lesions that resist further 
treatment (Phillips et al., 2006). Adding to this complication, the brain is enveloped 
in a protective blood brain barrier that limits the delivery of polar compounds to the 
central nervous system that have large molecular weights, such as proteins 
(Reardon and Wen, 2006). Additionally, chemotherapeutic agents are often 
actively pumped out of the brain by efflux pumps (Fletcher et al., 2010). Even 
when chemotherapeutic agents reach the lesion, the highly heterogenous genetic 
profile of these neoplasms ensures that not all cells are effectively treated 
(Reardon and Wen, 2006). With all these challenges, patient outcomes remain 
highly variable (Sulman and Aldape, 2011). It is therefore clear that new agents 
that more closely target the biology of the disease need to be developed in order 
to improve on treatment options for this lethal disease. 
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Genetic Aberrations of Primary and Secondary GBM 
 
Although it is still unclear what the cell of origin is for primary and 
secondary GBM (Furnari et al., 2007), it has been proposed that primary GBM 
arises from glial progenitor cells that have accumulated distinct genetic alterations 
(Ohgaki and Kleihues, 2011). These include epidermal growth factor receptor 
(EGFR) amplification / mutations / rearrangement, tumor protein 53 (TP53) 
mutations, phosphatase and tensin homolog (PTEN) mutations, 
neurofibromatosis-1 (NF1) alterations, and loss of heterozygosity (LOH) of 10p 
and 10q (Ohgaki and Kleihues, 2011). Other genetic alterations that occur in 
primary GBM are INK4a/ARF mutations, Cyclin D1/3 amplification or 
overexpression, murine double minute 2/4 amplification or overexpression, and B-
Cell CLL/Lymphoma 2 Like Protein overexpression (Furnari et al., 2007).  
There is evidence to suggest that secondary GBM originates from 
progenitor cells that acquire an isocitrate dehydrogenase 1/2 (IDH1/IDH2) 
mutation (Yan et al., 2009). IDH1/2 mutations occur in the majority of WHO Grade 
II diffuse astrocytomas, and the frequency of mutation does not increase with 
tumor grade (Ohgaki and Kleihues, 2011). The mutation status of IDH1/2 
correlates favorably with a better prognosis for GBM patients. Patients are 
predicted to survive as long as 31 months if their tumors have an IDH1/2 mutation, 
versus half that survival time for patients whose tumors do not have an IDH1/2 
mutation (Yan et al., 2009). Later, is was also shown that an IDH1 mutation status 
held a lot of predictive power in assessing improved patient survival after surgical 
resection and radiotherapy, with the mean survival being 27.1 months versus 11.3 
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months for those patients whose tumors did not have an IDH1 mutation 
(Nobusawa et al. 2009). Additionally, diffuse astrocytomas have mutations in 
TP53, and anaplastic astrocytomas acquire LOH of 10q (Ohgaki and Kleihues, 
2011). 
Key genetic alterations that play important roles in the development of 
primary and secondary GBM are represented in Figure 1. 
 
 
 
 
Figure 1. Genetic aberrations associated with the development of primary 
and secondary GBM. [mutation (mut), overexpression (OE); loss of heterozygosity 
(LOH)]. 
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GBM Subtypes 
 
Using high-throughput expression profiling techniques, GBM has been 
further classified into various subtypes based on their gene expression profiles 
(Phillips et al., 2006; Verhaak et al., 2010). The first of these studies by Phillips 
and colleagues (2006) identified three GBM subclasses, with those being 
mesenchymal, proneural, and proliferative. They reported that the proneural 
subclass had a gene expression signature that displayed neuronal lineage 
markers. Patients with these tumors tended to live longer than patients with 
tumors expressing mesenchymal (angiogenic) or proliferative markers. Analysis 
using array comparative genomic hybridization methodologies identified that both 
the poor prognostic groups had gains or amplification of the EGFR, which was not 
seen in the proneural GBM subtype. Remarkably, the two poor prognosis 
subtypes also expressed elevated levels of neural stem cell markers compared 
with proneural tumors. Their results also showed that if a patient’s initial lesion 
displayed proneural or proliferative markers, then the recurrent tumors would shift 
their gene expression signature to represent that of the mesenchymal subtype. 
The recurrent tumors were frequently upregulated in YKL-40, CD44, STAT3 and 
vimentin; all markers of the mesenchymal-angiogenic phenotype (Phillips et al., 
2006). Importantly, these studies have led to the identification of a set of genes, 
representing both the proneural and mesenchymal GBM subtypes, which has 
been developed into a clinical test, compatible with how samples are processed 
following resection, which predicts patient outcome (Colman et al., 2010). 
Furthermore, these multigenes are currently being used to stratify patients in a 
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large multi-center Phase III clinical trial (RTOG 0825) that determines whether the 
addition of bevacizumab (Avastin; anti-VEGF; anti-angiogenic) to standard care 
regimens improves survival (http://clinicaltrials.gov; Sulman and Aldape, 2011). 
The second high-throughput profiling study that I would like to mention 
stratified GBM molecularly in terms of gene expression signatures into four major 
subtypes; proneural, neural, classic, and mesenchymal, (Verhaak et al., 2010). 
Patterns of mutation and DNA copy number alterations were also integrated into 
their analyses. They reported that the proneural signature had PDGFRA/IDH1 
genetic aberrations, while the classic and mesenchymal GBM subtypes contained 
mainly EGFR and NF1 aberrations, respectively. EGFR amplification was found in 
as many as 95% of classic GBM tumors, and in at least 29% of those classified as 
being mesenchymal. Increased copy numbers for both the hepatocyte growth 
factor receptor (c-Met) and EGFR were seen in >86% of all GBM subclasses, 
except for those tumors classified as being proneural. 
These groundbreaking reports may lead to the identification of prognostic 
and predictive markers that correlate with treatment response. Better therapies 
could then be explored, with the ultimate goal of eventually being able to 
personalize medicine (Sulman and Aldape, 2011). 
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Dysregulated Receptor Tyrosine Kinases in GBM 
 
The Cancer Genome Atlas (TCGA) Network (The Cancer Genome Atlas 
Research Network, 2008) performed a comprehensive analysis of aberrations that 
occur in GBM. They reported that there are three major pathways with 
components that have significant alterations, with those being the receptor driven 
RAS / phosphitidylinositol 3-kinase (PI3K) (88%), the NF1 (87%), and the p53 
(78%) pathways.  
 Receptor tyrosine kinases (RTKs) are often aberrantly overexpressed and 
overactive in human cancer, including GBM, and therefore targeting RTK 
dysregulation has become a key strategy for targeted therapy (Krakstad and 
Chekenya, 2010). The increased activation of RTKs occurs through ligand-
dependent and ligand-independent mechanisms (Li et al., 2007; Pillay et al., 
2009; Shinomiya et al., 2004). These include, amplification of RTK signaling by 
their ligands (Shinomiya et al., 2004), constitutive activation of receptors by 
missense mutations or multiple exon deletion (Pillay et al., 2009), and receptor 
crosstalk with resultant activation (Eder et al., 2009). Increased RTK expression 
and activation in cancer cells contributes significantly to hallmark malignancy 
phenotypes, such as increased proliferation, survival, invasion, glycolysis, cell 
growth, and angiogenesis (Figure 2; Bertotti et al., 2009; Frederick et al., 2000;   
Pillay et al., 2009; Wong et al., 1992). Although Figure 2 provides an incomplete 
picture of all possible cellular events that may occur in response to RTK 
dysregulation, the main molecular players involved in PI3K and mitogen activated 
protein kinase (MAPK) pathway activation are shown. 
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Figure 2. Biological responses of PI3K and MAPK pathway dysregulation. 
 
 
EGFR 
 
The EGFR (also known as HER1 / ErbB1) belongs to a larger family of 
ErbB receptors with tyrosine kinase activity (Ymer et al., 2011). Other members of 
this commonly linked ancestral family include ErbB2 (HER2/neu), ErbB3 (HER3) 
and ErbB4 (HER4) (Huang et al., 2009).  These EGFR family members regulate 
diverse cellular processes, such as proliferation, migration, survival, adhesion, 
and differentiation, which are important in normal development, and if 
dysregulated may contribute to the development of cancer (Yarden and 
Sliwkowski, 2001). EGFR family members share common domain organization, 
with those being an extracellular ligand binding domain, a transmembrane 
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domain, and an intracellular domain. The intracellular domain consists of a 
tyrosine kinase domain and a c-terminal tail with multiple tyrosine residues that 
can be autophosphorylated following receptor dimerization and activation (Huang 
et al., 2009). Canonically, the wild type (WT) EGFR may be activated by seven 
different ligands (Schneider and Wolf, 2009); epidermal growth factor (EGF), 
transforming growth factor-α (TGF-α), heparin-binding EGF-like growth factor (HB-
EGF), amphiregulin, betacellulin, epiregulin, and epigen (Villares et al., 2007). 
Ligand binding is crucial for the EGFR to homodimerize, or to heterodimerize with 
other ErbB family receptors, so that activation and autophosphoryation can occur 
(Ymer et al., 2011). The preferred autophosphorylation site of the WT EGFR is 
Y1173 (Schmidt et al., 2003), however others such as Y1068 and Y1148 are also 
indicative of its tyrosine kinase activity (Huang et al., 2009). The tyrosine residue, 
Y1045, is a c-Cbl binding site that serves to downregulate the receptor after it has 
been stimulated with ligand and ubiquitinated (Grovdal et al., 2004). The Y845 site 
of EGFR is phosphorylated by Src family non-receptor protein tyrosine kinases 
following their activation by the EGFR (Yamamoto et al., 2006). 
 
 
EGFR Alterations in GBM 
 
EGFR is overexpressed in approximately 60% of primary GBM cases and 
in less than 10% of patients with secondary GBMs (Ohgaki and Kleihues, 2007), 
indicating that EGFR alterations occur predominantly in aggressive cases. Several 
mechanisms may additionally account for aberrant EGFR signaling in GBM, with 
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one being the upregulated autocrine expression of its ligands (Huang et al., 2009; 
Ramnarain et al., 2006; Singh and Harris, 2005). Enhanced EGFR activation in 
GBM may also be caused by amplification or mutation, which taken together is 
found in as many as 45% of all GBMs (The Cancer Genome Atlas Research 
Network, 2008). Almost every classic GBM has focal amplification of the EGFR, 
with the mesenchymal, neural, and proneural tumors amplifying the EGFR at 
29%, 67%, and 17%, respectively (Verhaak et al., 2010). EGFR mutations are 
also a frequent occurrence in GBM and are found in about a third of all tumors 
belonging to the classic GBM subclass, and in many of the proneural, neural and 
mesenchymal tumors (Verhaak et al., 2010).  Various point mutations in the 
extracellular domain of the EGFR account for some of these aberrations (Lee et 
al., 2006). During the amplification process, the EGFR gene is often rearranged, 
which may also result in transcripts with large deletions (Cavenee, 2002). The 
most common rearrangement of the EGFR gene is an in-frame 2-7 exon deletion 
within the extracellular domain, and is known as ΔEGFR (de2–7 EGFR, EGFRvIII, 
or EGFR*) (Ohgaki and Kleihues, 2007).  
 
 
ΔEGFR 
 
The in-frame 801bp deletion of the ∆EGFR gene results in a truncated 
protein unable to bind its cognate ligands (Schmidt et al., 2003). Despite this, the 
∆EGGR signals constitutively at a low-level, thereby successfully allowing it to 
evade signals regulating internalization and downregulation (Huang et al., 1997; 
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Hwang et al., 2011). This is in contrast with ligand-stimulated WT EGFR that is 
rapidly attenuated following acute stimulation with ligand (Schmidt et al., 2003). 
One of the primary reasons for the low signal intensity of the ∆EGFR is due to 
inefficient dimerization (Hwang et al., 2011; Ymer et al., 2011). However, its 
constitutive signal leads to increased survival of GBM cells in vivo, by augmenting 
mitogenic effects and reducing apoptotic rates (Nagane et al., 1996). Interestingly, 
when ∆EGFR is used to transform INK4A/Arf depleted astrocytes and neural stem 
cells, high grade lesions are orthotopically and subcutaneously produced when 
injected into nude mice (Bachoo et al., 2002), raising the possibility that it may be 
one important initiating event in tumor development. Not only is ∆EGFR most 
likely an important factor in gliomagenesis, but the tumorigenic potential of glioma 
cells in vivo are significantly enhanced by ∆EGFR expression when compared 
with those xenografts expressing the WT EGFR (Cavenee, 2002; Huang et al., 
1997; Nishikawa et al., 1994).  It has also been shown that cells expressing 
∆EGFR are inherently recalcitrant to both radiation (Lammering et al., 2004) and 
chemotherapy (Nagane et al., 1998). ∆EGFR also activates the PI3K-Akt-mTOR 
pathway to a greater degree than the Ras-Raf-MEK cascade, and recruits the 
activity of STATs (STAT3 and STAT5b) for enhanced cellular proliferation, 
viability, and transformation (Chumbalkar et al., 2011; de la Iglesia et al., 2008; 
Huang et al., 2009). Not surprisingly, ∆EGFR expression has been strongly 
associated with a poor survival prognosis for patients whose tumors amplify 
EGFR (Heimberger et al., 2005; Shinojima et al., 2003), or express YKL-40 
(Pelloski et al., 2007). 
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∆EGFR in GBM 
 
The ∆EGFR is not detected in normal tissues, and is therefore a cancer 
specific mutant of the EGFR (Wikstrand et al., 1998). Several studies have shown 
that the ∆EGFR is expressed in about 45-50% of GBMs that amplify the WT 
EGFR (Pedersen et al., 2001; Shinojima et al., 2003; Wikstrand et al., 1998). In a 
more recent study performed by the TCGA Network, the ∆EGFR deletion is mostly 
found in the classic GBM subclass (23%), a subclass amplifying EGFR the most 
compared with other GBM subclasses, and in 3% of proneural and mesenchymal 
GBMs (Verhaak et al., 2010). However, the 200 GBMs analyzed in this study may 
have had a negative selection bias towards the ∆EGFR, as necrotic tissue, which 
is frequently found in high grade GBM (Li et al., 2009), was limited to 40% of each 
sample (Verhaak et al., 2010). Most likely the ∆EGFR was not detected in as 
many GBMs as previously reported, due to the patchy expression of ∆EGFR 
(Wiesner et al., 2009) in only a small percentage of the total number of cells in a 
GBM (Jungbluth et al., 2003). 
 
 
Targeting EGFR / ∆EGFR in GBM 
 
Given that the EGFR is highly dysregulated in GBM, it is surprising that 
EGFR inhibitors, including tyrosine kinase inhibitors (TKIs) that also target the 
∆EGFR, have not lived up to their clinical promise (Halatsch et al., 2006). 
Resistance to anti-EGFR therapy has been partly attributed to signal 
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compensation by other RTKs, or via their transactivation by EGFR and ∆EGFR, 
leading to the persistent activation of redundant signaling pathways (Camp et al., 
2005; Pillay et al., 2009). It has therefore become critically important to identify 
key players that mediate their signal and maintain their biological characteristics. 
 
 
c-Met  
 
 c-Met is a RTK essential for normal physiological and developmental 
programs, such as branching morphogenesis, wound repair, organ patterning, 
and organ homeostasis (Birchmeier et al., 2003; Trusolino et al., 2010). It is also a 
protein highly active in most cancers, regulating processes such as metastasis, 
angiogenesis, proliferation, survival, and invasion (Bardelli et al., 1997; Birchmeier 
et al., 2003; Sheth et al., 2008). c-Met is produced as a glycosylated 170 kDa 
precursor protein that is cleaved by proteases into a 50 kDa α-chain and a 145 
kDa β-chain, which are linked by disulphide bridges (Crepaldi et al., 1994). The β-
chain spans the membrane, having an intracellular tyrosine kinase domain and a 
large extracellular domain, and the α-chain is located extracellularly (Ma et al., 
2003; Figure 3).  
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Figure 3. c-Met structural domains, major tyrosine phosphorylation sites, 
and binding partners. 
 
 
The hepatocyte growth factor (HGF), c-Met’s only known activating 
physiological ligand, binds c-Met in the sema (Gherardi et al., 2003) and IP3/IP4 
domains (Trusolino et al., 2010). The sema domain, also found in semaphorins 
and plexins (Trusolino et al., 2010), is equally important for receptor dimerization 
(Kong-Beltran et al., 2004). c-Met’s intracellular region contains a juxtamembrane 
domain, tyrosine kinase catalytic domain, and a multi-functional docking site. All 
three intracellular domains contain tyrosine residues that are phosphorylated 
upon ligand binding (Hov et al., 2004).  
Phosphorylation of c-Met Y1003 has been shown to be important for Cbl-
mediated ubiquitination and degradation following receptor internalization (Abella 
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et al., 2005; Li et al., 2007). The c-Met signal may also be downregulated by 
decorin, an extracellular small leucine-rich proteoglycan, within first few minutes 
of their association (Goldoni et al., 2009). Attenuation of c-Met signaling by 
disintegrin and metalloprotease-mediated extracellular domain cleavage, 
produces a soluble N-terminal fragment that is capable of sequestering HGF 
present in the extracellular environment; a process known as shedding. This 
‘decoy’ fragment may also interfere with c-Met dimerization, ultimately leading to 
signal attenuation. The membrane-anchored cytoplasmic tail is proteolytically 
cleaved by γ-secretase and then degraded (Foveau et al., 2009).  
Phosphorylation of Y1234 and Y1235 of c-Met, which are located in the kinase 
domain, are required for full receptor activation (Bardelli et al., 1997). In the 
absence of activating mutations, Y1235 is the first tyrosine residue in the 
autophosphorylation (kinase) domain to be phosphorylated, which is then followed 
by Y1234 phosphorylation (Chiara et al., 2003). Once this occurs, phosphorylation 
at Y1349 and Y1356 in the COOH terminus links Src homology 2 domain 
containing signaling adapters and transducers to the receptor for initiation of 
signal transduction (Peruzzi and Bottaro, 2006). These adapter proteins and 
signaling effectors (listed in Figure 2) signal primarily through the PI3K signaling 
cascade, signal transducer and activator of transcription proteins (STATs), MAPK 
pathways, and the nuclear factor-κβ inhibitor-α – nuclear factor-κβ complex 
(Birchmeier et al., 2003; Trusolino et al., 2010). 
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Amplification of the c-Met Signal 
 
c-Met signal amplification may occur via its interaction with the α6β4 
integrin at the plasma membrane, which acts as an additional docking platform for 
signaling adapters and transducers (Bertotti et al., 2006). Another protein that 
intensifies the c-Met signal at the cell surface is the v6 splice variant of CD44, 
which is a cell adhesion molecule connecting the extracellular matrix to the 
cellular actin cytoskeleton. The ternary structure produced by the interaction of c-
Met, CD44v6 and HGF activates c-Met, which in turn results in the activation of 
Ras, a MAPK pathway signaling effector (Trusolino et al., 2010). Ligand-
independent strengthening of the c-Met signal may also occur through 
interactions with semaphorin receptors at the plasma membrane, such as is the 
case with class B plexins and neuropilin (Knutsen and Vande Woude, 2008). 
Recently it was shown that in non-small cell lung cancer (NSCLC) cases that 
acquired resistance to EGFR inhibitors, c-Met became amplified and its signal 
transduced via ERBB3 activation (Engelman et al., 2007). Additionally, c-Met 
interacts with the RON receptor tyrosine kinase, which it shares a great deal of 
sequence homology with, and with the EGFR (Gentile et al., 2008), which will be 
expanded upon later.  
The compartmentalization of c-Met signaling on endosomes has gained a 
lot of attention lately. After c-Met is stimulated by ligand and internalized by 
clathrin-mediated endocytosis, the c-Met signal sustains ERK activation at 
peripheral early endosomes. Activated ERK then translocates to cell adhesion 
sites at the plasma membrane, which is mediated by protein kinase Cε, where cell 
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migration is initiated (Kermorgant et al., 2004). The delivery of c-Met along 
microtubules to the perinuclear compartment allows for the rapid activation and 
translocation of STAT3 into the nucleus (Kermorgant and Parker, 2008), which 
most likely shields STAT3 from phosphatases that may attenuate its signal 
(Trusolino et al., 2010). Recently, Joffre and colleagues (2011) showed that 
active, cancer-specific, c-Met mutants accumulate on endosomes due to 
enhanced rates of endocytosis and reduced receptor degradation. Additionally, 
they showed that c-Met aggregation on endosomes activates Rac1, which 
ultimately leads to increased cell migration. When they blocked endocytosis, 
which did not affect c-Met activity, tumorigenicity and metastasis were reduced in 
vivo. Therefore, compartmentalization of the c-Met signal may serve to enhance 
tumorigenicity by temporally spacing preferential signaling partners. 
 
 
The c-Met / HGF axis in GBM 
 
In normal tissues, HGF that is secreted by mesenchymal cells activates c-
Met on epithelial cells in a paracrine manner (Gentile et al., 2008; Moriyama et al., 
1998; Wojcik et al., 2006). In cancer (Hung and Elliott, 2001; Hov et al., 2004; 
Rahimi et al., 1996), including GBM, both receptor and ligand pair are often 
coexpressed, which establishes a permissive microenvironment for sustained 
oncogenic signaling through c-Met (Abounader et al., 2005).  
In 1997, Nabeshima and colleagues used immunohistochemistry to 
examine the expression of c-Met across increasing grades of astrocytic tumors. 
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They found that c-Met protein expression was enhanced in GBM compared with 
tumors that represented lower grades of glioma.  Similarly, HGF protein 
expression increases with glioma grade (Kunkel et al., 2001).  
In total, there have been three studies published that have examined the 
coexpression of c-Met and HGF in GBM. The first study by George F. Vande 
Woude’s research group (Koochekpour et al., 1997) used double 
immunofluorescence staining to show that HGF and c-Met expression increased 
with glioma grade. These authors also found that costaining of c-Met and HGF 
was present in 13 out of 15 GBMs. Soon after their discovery, Moriyama and 
colleagues (1998) analyzed HGF and c-Met messenger ribonucleic acid (mRNA) 
expression in GBMs. They found that their mRNA expression increased with 
astrocytic tumor grade, and that both c-Met and HGF were coexpressed in 6 of 15 
GBMs. A subsequent study analyzed the mRNA expression of HGF and c-Met in 
a subset of 43 GBM tumors using Affymetrix U133 arrays (Beroukhim et al., 
2007). They showed that c-Met and HGF, which are located on chromosome 7 
(Beau-Faller et al., 2008), were mostly coexpressed in GBM samples with broad 
gains of chromosome 7 (P < 0.06). Trisomy of chromosome 7 is frequently found 
(70%) in GBMs (Piccirillo et al., 2009), indicating that this signaling axis plays a 
pivotal role in this tumor.  
Not surprisingly, tumorigenicity was significantly enhanced upon the 
intracranial implantation of HGF-overexpressing GBM cells into mice (Laterra et 
al., 1997). This degree of tumorigenicity was reversed through the use of 
U1snRNA/ribozymes that targeted c-Met or HGF in established GBM xenografts 
(Abounader et al., 1999; Abounader et al., 2002). Further, other investigators 
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have shown that inhibition of c-Met’s activity in intracranial GBM xenografts 
impairs tumor growth (Buchanan et al., 2009; Tseng et al., 2008). However, GBM 
tumors that are not addicted to the c-Met / HGF axis, meaning that these 
molecules are not highly expressed and signaling, are unresponsive to c-Met 
inhibition (Martens et al., 2006). These studies have been further expanded to 
provide evidence that high-level expression of c-Met correlates with a worse 
survival prognosis for GBM patients, when compared with those GBM patients 
whose tumors did not express c-Met (Kong et al., 2009). 
 
 
Cross-talk between the EGFR / ∆EGFR and c-Met Pathways 
 
A complex relationship exists between EGFR and c-Met signaling, where 
HGF-mediated c-Met activation increases EGFR ligand expression (TGF-α and 
HB-EGF), thereby aiding in EGFR dysregulation (Reznik et al., 2008). Once 
EGFR is activated by TGF-α and HB-EGF, c-Met expression may be stimulated in 
a HIF-1α hypoxia-independent manner (Xu et al., 2010).  
Although c-Met is primarily activated by its ligand, HGF, the ligand-
independent activation of c-Met is emerging as an important contributing factor to 
aberrant c-Met signaling (Yamamoto et al., 2006). Transactivation of c-Met by the 
EGFR in cancer cells was first described by Jo and colleagues (2000). They 
showed that upon EGFR stimulation by TGF-α that c-Met was activated, which 
could be reversed with TGF-α and EGFR antagonists. Since then, c-Met 
activation by EGFR has been confirmed in various cancer cell lines (Bergström et 
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al., 2000; Bonine-Summers et al., 2007; Fischer et al., 2004; Pai et al., 2003), 
suggesting that the EGFR signals through c-Met. This interaction has been 
reported to be by direct association (Agarwal et al., 2009), and potentially 
unidirectional, until a recent study showed that amplified c-Met is capable of 
transactivating the EGFR (Bachleitner-Hofmann et al., 2008). 
By enriching for phosphotyrosine peptides, Huang and colleagues (2007) 
used mass spectrometry to examine preferential signaling of ∆EGFR in U87 GBM 
cells. They overexpressed titrated levels of ∆EGFR in U87, and asked which 
specific signaling events were most strengthened by the ∆EGFR signal. They 
discovered that Y1234 of c-Met, which is a good indicator of its overall activation 
(Chiara et al., 2003), was steadily activated with increased expression of ∆EGFR. 
This indicated that c-Met activation was downstream of ∆EGFR signaling, and that 
c-Met activity could be regulated by ∆EGFR in GBM cells. Additionally, they found 
that c-Met inhibition could circumvent ∆EGFR-mediated chemoresistance in U87 
cells.  
Recently, our laboratory examined signaling differences in GBM cells by 
mass spectrometry after tyrosine enrichment when ∆EGFR, kinase-inactive 
∆EGFR (∆EGFR-ki), or WT EGFR was expressed, and when WT EGFR was 
stimulated with EGF, which showed that c-Met is a preferential target of the 
∆EGFR even when compared with EGF-stimulated EGFR (Chumbalkar et al., 
2011). c-Met activation was also examined in U87 xenografts expressing either 
WT EGFR, ∆EGFR, or ∆EGFR-ki, where it was found that c-Met activation was 
enhanced in those tumors expressing ∆EGFR (Chumbalkar et al., 2011). Another 
group suggested that the kinase activity of ∆EGFR, and not autophosphorylation, 
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is necessary to coactivate c-Met in a ligand-independent manner in GBM cells 
(Pillay et al., 2009). Furthermore, their finding that when using EGFR and HGF 
antagonists in combination to treat ∆EGFR-expressing c-Met-/HGF-dependent 
GBM xenografts that a significant reduction in tumor growth would occur 
compared with either agent alone, suggests the clinical potential of combination 
therapy (Pillay et al., 2009). 
 
 
Regulation of c-Met and HGF Expression 
 
Aside from chromosome 7 trisomy (Beroukhim et al., 2007), mechanisms 
governing aberrant HGF regulation in GBM have not yet been identified. 
Functional studies in other cancer cell lines have highlighted the importance of the 
transcriptional induction of the HGF gene as a major cause of dysregulated 
autocrine HGF circuitry (Hung and Elliott, 2001; Wojcik et al., 2006). HGF gene 
transcription in human cells has been shown to be regulated in the proximal 
promoter at a Stat3-binding element (-99/-91; TTACCGTAA) (Tomida and Saito, 
2004). Similarly, in mouse mammary carcinoma cells a -95 STAT3 consensus site 
in the HGF gene was linked to aberrant HGF expression, which promoted 
transformation (Wojcik et al., 2006). STAT3 signaling is required for the 
maintenance of the aggressive mesenchymal phenotype in GBM, and its 
expression (Carro et al., 2010) or activity (Birner et al., 2010) is a negative 
prognostic factor for GBM patients. More than 90% of GBM tumors have elevated 
STAT3 activity (Rahaman et al., 2002), which has been found to be imperative for 
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c-Met / HGF-mediated anchorage-independent growth and tumorigenicity in vivo 
(Zhang et al., 2002). c-Met is capable of activating STAT3 directly or indirectly 
(Birchmeier et al., 2003), and once activated, it homodimerizes, or 
heterodimerizes with other STAT family members, and translocates to the nucleus 
where it controls gene expression by binding to promoter elements (Song et al., 
2003).  
In the 5’ flanking region of the mouse HGF promoter, a Sp1 binding site (-
318 to -303) binds Sp1 and Sp3 transcription factors to regulate HGF expression 
(Jiang et al., 1997). Later, p53 was also found to regulate the mouse HGF 
promoter (Seol et al., 1999). HGF may also be regulated in the basal promoter 
region (-4 to +3 from the transcription start site) by CCAAT/ enhancer-binding 
protein β (C/EBPβ) / C/EBPς. Binding of C/EBPβ to the HGF promoter could be 
induced by the action of several cytokines, such as IL6, IL-1, TNF-α, and TGF-α. 
Later, Jiang and colleagues (2001) also found that the mouse HGF promoter 
bound ligand-activated peroxisome proliferator-activated receptor γ at - 246 to -
233 bp upstream from the HGF gene’s transcription start site.  
c-Met overexpression in GBM occurs through amplification (4-20%; Mueller 
et al., 1997; The Cancer Genome Atlas Research Network, 2008), rare missense 
mutations (Moon et al., 2000), upregulation of its transcriptional activity 
(Abounader and Laterra, 2009; Kong et al., 2009), chromosome 7 trisomy  
(Beroukhim et al., 2007), and through HGF-mediated activation of the c-Met 
receptor (Abounader et al., 2001). c-Met stimulation by HGF not only induces the 
expression of c-Met in GBM cells, but it also does so in lung adenocarcinoma cells 
(Boccaccio et al., 1994). Since positive regulatory loops have also been described 
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for other receptors and their ligands (Caolo et al., 2010; Chen et al., 2010; Clark et 
al., 1985; Reem et al., 1984), we hypothesized that the enhanced levels of 
autocrine HGF expression in GBM may additionally hinge on the action of c-Met. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
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Cell Culture 
 
The U87MG and LN18 human GBM cells were originally obtained from the 
American Type Culture Collection, and cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM 
glutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin. GBM cell lines were 
cultured under normal growth conditions; 7% CO2 and 37°C in a humidified 
incubator. Dr. Zhimin Lu (The University of Texas M. D. Anderson Cancer Center) 
generously provided us with Madin-Darby Canine Kidney (MDCK) cells.  Human 
Embryonic Kidney 293FT cells were a kind gift from Dr. Howard Colman (The 
University of Utah). These cells were cultured under normal conditions in a 
humidified chamber that delivered 5% CO2 at 37°C. To establish identity, U87 and 
LN18 GBM cells were DNA fingerprinted using a polymerase chain reaction 
(PCR)-based approach (GenomeLab Human Short Tandem Repeat Primer set 
from Beckman Coulter) (Table 1). 
 
Table 1. Short 
tandem repeat fingerprinting 
of GBM cells. U87 and 
LN18 cells were analyzed 
for their specific marker 
allele content for 
comparative purposes and 
identification. 
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Antibodies 
 
The following primary antibodies were purchased from Cell Signaling and 
used at the indicated final concentration: anti-c-Met (1:1000), anti-pc-Met 
(Y1234/Y1235) (1:1000); anti-EGFR (1:1250), anti-pEGFR (Y1173) (1:1000), anti-
STAT3 (1:1000), and anti-pSTAT3 (Y705) (1:1000). We obtained the anti-HGF 
primary antibody from R&D Systems; it was diluted to a final concentration of 
1:1000 for western blot (WB) analysis. For actin detection on western blots, we 
used an anti-β-actin conjugated to horseradish peroxidase (1:50000) that was 
purchased from Sigma. Secondary antibodies that were used were as follows: 
anti-mouse secondary antibody (1:3000; Fisher Scientific); anti-rabbit secondary 
antibody (1:20000; Jackson Immunoresearch Laboratories); and an anti-goat 
secondary antibody (1:3000; Santa Cruz). For HGF neutralization experiments, 
we used the HGF primary antibody at a final concentration of 0.6 µg/ml. 
 
 
Reagents 
 
The recombinant human HGF that was used in our studies was obtained 
from Chemicon. The c-Met kinase inhibitor, SU11274, and the EGFR kinase 
inhibitor, AG1478, were purchased from Calbiochem. Actinomycin D was obtained 
from Sigma-Aldrich. Hygromycin B, G418, and puromycin were obtained from 
Fischer Scientific. WP1193 was a generous gift from Dr. Waldemar Priebe (The 
University of Texas M. D. Anderson Cancer Center). 
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shRNA Infection of GBM Cells 
 
HEK 293FT cells were cultured to 50% confluence in 10 cm plates and 
transfected with short hairpin ribonucleic acids (shRNAs) targeting c-Met (1 µg; 
pLK0.1 backbone; Open Biosystems) or a non-targeting scrambled shRNA (1 µg; 
pLK0.1 backbone, Addgene number 1864), and pCMV-dR8.2 dvpr (0.9 µg; 
Addgene number 8455), and pCMV-VSVG (0.1 µg; (Addgene number 8454) 
(kindly shared by Dr. Ta-Jen Liu, U.T. MD Anderson Cancer Center), with 6 µL 
Fugene HD (Roche), according to the manufacturer’s instructions. After 48 h, the 
viral supernatant was filter sterilized through a 0.45 µM syringe filter, and either 
stored at -80° or applied to 50% confluent U87 GBM cells after the addition of 
hexadimethrine bromide (8 µg/mL). After 3 h of infection, viral supernatant was 
removed and fresh media added to the cells. After 48 h, cells were split and 
selected with puromycin (1 µg/mL) for 6 days. Cloning by limiting dilution was 
performed to obtain clonal populations of U87 sh-c-Met clones. Details of the c-
Met shRNA pLKO.1 hairpin sequences may be found in Table 2. 
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Open Biosystems # 
Label 
Strand Sequence Accession# 
TRCN0000009850 
sh-c-Met #A 
sense 5’-CAGAATGTCATTCTACATGAG-3’ NM_001127500.1 
antisense 5’-CTCATGTAGAATGACATTCTG-3’ NM_001127500.1 
TRCN0000040047 
Sh-c-Met #B 
sense 5’-GCCAGCCTGAATGATGACATT-3’ NM_001127500.1 
antisense 5’-AATGTCATCATTCAGGCTGGC-3’ NM_001127500.1 
 
Table 2. pLKO.1 c-Met shRNA targeting constructs. Sequence and 
sequence identifying information of the c-Met shRNA targeting sequences. 
 
 
 
Generation of Kinase-deficient c-Met Plasmids 
 
An internal 2kb fragment was restricted out of pMSCV-wt c-Met (a 
generous gift from Dr. Lisa Elferink, UTMB) with Apa1, and the Apa1 ends of the 
pMSCV-wt c-Met plasmid ligated to generate a pMSCV-wt c-Met (∆Apa1) plasmid. 
QuickChange site-directed mutagenesis (Stratagene) was performed to create the 
pMSCV-c-Met Y1234 (∆Apa1) and pMSCV-c-Met Y1235 (∆Apa1) mutants; 
primers that were used are listed in Table 3. Next, the gel-purified internal 2kb 
fragment (generated as previously described) was ligated into the pMSCV-c-Met 
Y1234 (∆Apa1) and pMSCV-c-Met Y1235 (∆Apa1) mutant expression vectors that 
had been restricted with Apa1 to generate the pMSCV-c-Met Y1234 and pMSCV-
c-Met Y1235 plasmids. 
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Mutation Strand Sequence Accession# 
c-Met Y1234F 
sense 
5’-GAGACATGTATGATAAAGAATTCTAT 
AGTGTACACAACAAAAC-3’ 
NM_001127500.1 
antisense 
5’-GTTTTGTTGTGTACACTATAGAATTC 
TTTATCATACATGTCTC-3’ NM_001127500.1 
c-Met Y1235F 
sense 
5’- CATGTATGATAAAGAATACTTTAGTGT 
ACACAACAAAACAGG-3’ NM_001127500.1 
antisense 
5’- CCTGTTTTGTTGTGTACACTAAAGTAT 
TCTTTATCATACATG-3’ NM_001127500.1 
 
Table 3. Primers used to generate kinase-deficient c-Met mutants. 
 
 
 
Transfection and Retroviral Infection 
 
A constitutively active STAT3 (STAT3-CA) in a pcDNA3.1/Hygro(+) vector 
was kindly provided by Dr. Robert Arceci (Johns Hopkins, Baltimore, MD, USA) 
(Ning et al., 2001). The constitutively active STAT3 contains Cys substitutions at 
Ala662 and Asn664 (Bromberg et al., 1999). The pcDNA3.1/Hygro(+) empty 
vector was a generous gift from Dr. Suyun Huang (MD Anderson Cancer Center). 
STAT3-CA and empty vector were transfected into 50% confluent U87-∆EGFR 
cells using Fugene HD (Roche), according to the manufacturer’s instructions. 
After 48 h, the cells were split and selected using 50 μg/mL Hygromycin B. 
10 μg pLRNL-∆EGFR (a generous gift from Dr. H-J Huang, UCSD), 
pMSCV-puro empty vector, pMSCV-wt c-Met, pMSCV-c-Met P991S, pMSCV-c-
Met Y1003 (c-Met plasmids were kind gifts from Dr. Lisa Elferink, UTMB), 
pMSCV-c-Met Y1234, and pMSCV-c-Met Y1235 was packaged into viral particles 
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using 50% confluent GP2 cells, pCMV-VSVG (10 μg) and Lipofectamine 2000, 
according to the manufacturer’s instructions (Invitrogen). After 48 hrs, viral 
supernatant was collected and sterilized through a 0.45 μM filter syringe. Viral 
supernatant was stored at -80°C for future use, or used to infect either 50% 
confluent U87 or U87 ∆EGFR GBM cells in T25 flasks using 0.8 μg/mL 
hexadimethrine bromide. After 3 h, the viral supernatant was removed and 
complete media added to the cells. When the dishes were confluent, the cells 
were split and selected using G418 (200 μg/mL) or puromycin (1 μg/mL) 
according to the selection marker present on the expression plasmid. 
 
 
Cell Lysate Preparation and Western Blotting 
 
For most western blot analyses, cells were cultured in 10% serum prior to 
collection. For all immunoprecipitation experiments, cells were cultured in serum-
free conditions for 20 h. Cells were then either collected, washed with phosphate 
buffered saline (PBS), and then scraped into ice-cold PBS. Pellets were gently 
resuspended in RadioImmunoPrecipitation (RIPA) lysis buffer (50mM Tris HCl pH 
7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium Deoxycholate, 0.1% SDS)  that 
contained phosphatase inhibitors (Sigma-Aldrich Cocktail Inhibitors I and II) and 
SigmaFAST protease inhibitor cocktail (Sigma-Aldrich), and then passed through 
a 21-gauge needle 10 times. Lysis proceeded on ice for 30 min before the 
supernatant was clarified from the cellular debris by centrifugation. Protein 
concentration was estimated colorimetrically using the Pierce BCA Protein Assay 
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Kit (Thermo Scientific), and lysates were stored at -20°C until further analysis. For 
western blot analysis, 20/30 µg protein was separated on 4-12% Bis-Tris NuPage 
gels (Invitrogen), except for HGF analysis where 150 ug of protein lysate was 
used. 
 
 
Immunoprecipitation Assays 
 
Total lysates were incubated with primary antibodies overnight with gentle 
rocking at 4°C. For the c-Met immunoprecipitation assay, an anti-c-Met antibody 
from R&D Systems was used. Subsequently, Protein G PLUS-Agarose beads 
from Santa Cruz bound the complexes. The beads were washed thrice using 
RIPA buffer, and then washed twice with ice-cold PBS. Immunoprecipitated 
proteins (500 μg) were resolved on 4-12% Bis-Tris NuPage gels, and analyzed 
using immunoblotting/western techniques that have been described. 
 
 
RNA Extraction and Quantitative Real-time PCR 
 
All cells were cultured in complete media in 10-cm diameter dishes until 
they reached 80% confluence. All cells were cultured under normal conditions. 
Cells were washed twice with PBS and scraped into ice-cold PBS. mRNA was 
extracted from the cell pellets using Qiagen’s RNeasy Mini Kit, and quantified 
using a NanoDrop 2000 instrument. Reverse transcription was performed with 
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Bio-Rad’s iScript cDNA Synthesis Kit. For the quantitative detection of transcripts, 
quantitative real-time PCR (qRT-PCR) was performed using FastStart SYBR 
Green Master reagent (Roche) with the primers that are detailed in Table 4. 
Samples were analyzed in duplicate/triplicate and normalized to an internal β-2-
microglobulin control. All experiments were repeated three times. 
 
Primer Strand Sequence Accession# 
HGF 
sense 5’-CTCACACCCGCTGGGAGTAC-3’ NM_000601.4 
antisense 5’-TCCTTGACCTTGGATGCATTC-3’ NM_000601.4 
BCL-XL 
sense 5’-GATCCCCATGGCAGCAGTAAAGCAAG-3’ NM_138578.1 
antisense 5’-CCCCATCCCGGAAGAGTTCATTCACT-3’ NM_138578.1 
β-2-
Microglobulin 
sense 5’-ATCCATCCGACATTGAAGTT-3’ NM_004048.2 
antisense 5’-GGCAGGCATACTCATCTTTT-3’ NM_004048.2 
 
Table 4. qRT-PCR primer sequences. Sequence of primers used in qRT-
PCR experiments.  
 
 
 
ELISA 
 
Cells were cultured in T225 flasks until they reached 80% confluence, 
washed twice in PBS, and cultured for 24 h in 40 mLs of serum-free media. 
Conditioned media (CM) from duplicate samples were pooled, centrifuged for 
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debris removal, and stored at -80°C until further analysis. Samples were 
concentrated using an Amicon concentrator using a regenerated cellulose 
ultrafiltration membrane with a 30,000 molecular weight cut off (Millipore). A 96-
well Nunc MaxiSorp plate was coated with 0.5 µg/mL mouse anti-human HGF 
monoclonal antibody (R&D Systems) or isotype control antibody diluted in PBS. 
Following an overnight incubation at room temperature (RT), wells were washed 
in PBS containing 0.05% Tween 20 (PBST), blocked for 1 hour at RT in 50mM 
Tris pH 8.0 containing 0.14 M NaCl, 1% BSA, and 0.05% Tween 20, and then 
washed with PBST. The concentrated samples, and a HGF standard, were 
serially diluted in Tris-buffered saline containing 0.1% BSA and 0.05% Tween 20 
(pH 7.3), and then 100µL of each sample was applied to wells of the plate. 
Additionally, in order to control for background noise of the assay, a media only 
control was added to three wells of the plate. Following an overnight incubation at 
4°C, wells were washed with PBST, and incubated for 2 hr at room temperature 
with 100 µL goat anti-human HGF polyclonal antibody (0.5 µg/mL; R&D Systems). 
After washing with PBST, 100 µL of HRP-conjugated bovine anti-goat IgG (40 
ng/mL; Jackson ImmunoResearch Laboratories Inc.) was added per well, and 
incubated for 1 hr at RT. Non-bound antibody was removed by washing with 
PBST. For the detection of HGF, QuantaBlu™ Fluorogenic Peroxidase Substrate 
(Thermo Fisher Scientific) was prepared according to the manufacturer’s 
instructions, and 100 µL added per well. The reaction was terminated after 30 min 
using QuantaBlu™ Stop Solution (Thermo Fisher Scientific), and the fluorescence 
(Ex325/Em420) measured using a SpectraMax Gemini (Molecular Probes) 
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fluorescent plate reader having SOFTmax Pro (v. 3.0) software. HGF ELISAs 
were performed twice. 
 
 
Luciferase Assays 
 
The human HGF promoter construct pGL2-HGF-1029 was a kind gift from 
Dr. Tomida, Saitama Cancer Center, Japan (Tomida and Saito, 2004). The 
1029bp sequence of the 5’-flanking region of the HGF gene was cloned into 
XhoI/HindIII sites of the luciferase reporter plasmid pGL2-basic (Promega).  
Cells were plated in six-well plates (1x105) the day before transfection. 
Fugene HD was used to transfect the HGF luciferase promoter constructs (1 
µg/well), or the pGL2 empty vector (1 µg/well), along with the pSV-β-
Galactosidase Control Vector (10 ng), using 3 µL Fugene HD (Roche) per well. 
After 48 h, lysates were prepared with the lysis buffer present in the Dual-Glo 
Luciferase Assay System (Promega) and analyzed for their luciferase activity 
according to the manufacturer’s instructions. β-galactosidase activity (Beta-Glo 
Assay System; Promega) was also measured in the lysates with a luminometer 
according to the manufacturer’s instructions. Transfection efficiency for each 
sample was normalized by calculating the luciferase activity to that of β-
galactosidase activity. A mean relative value was then calculated.  
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Anchorage-independent Growth Assays 
 
For colony formation, U87, U87 sh-c-Met #A2, U87 sh-c-Met #B2, U87 sh-
control ∆EGFR, U87 sh-c-Met #A2 ∆EGFR, and U87 sh-c-Met #B2 ∆EGFR cells 
were seeded at 7.5 x 102 cells / well in media containing 0.5% low-melting 
Agarose on a 0.7% low-melting agarose base in 24-well plates. U87 sh-control 
pcDNA3.1, U87 sh-control STAT3-CA, U87 sh-c-Met #B2 pcDNA3.1, and U87 sh-
c-Met #B2 STAT3-CA cells were plated at 1.5x103 cells / well in 12-well plates. 
After 1 h, 0.25 mL of media was added to wells of the 24-well plates, and 0.5 mL 
of media was added per well to the 12-well plates. Another aliquot of media was 
added to wells of the plates after 7 days in culture. Cells were cultured at 37°C in 
a humidified chamber receiving 7% CO2. Colony numbers were counted after 14 
days in culture using GelCount’s software and scanner. Additional experimental 
details have been previously described (Kajiwara et al., 2008). 
 
 
WST-1 Assays 
 
7.5 x 102 cells were plated per well of a 96-well plate in triplicate and 
cultured for 72 h at 37°C in a humidified chamber set to deliver 7% CO2. The 
WST-1 assay was performed according to the manufacturer’s specifications 
(Roche). 
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Intracranial Xenograft Studies 
 
8-12 wk old nude (nu/nu) mice were stereotactically injected with 2 x 105 
cells in 5 μL PBS into the right frontal lobe. Mice were maintained at The 
University of Texas MD Anderson Cancer Center’s Isolation Facility. Mice were 
euthanized when they started to show symptoms of neurological damage from the 
tumor burden, including but not limited to seizures, lethargy and paralysis. All 
animal experiments were performed on the same day. The maintenance and care 
of mice were conducted in accordance with Laboratory Animal Resources 
Commission standards under an approved protocol (100712131). 
 
 
Mass Spectrometry 
 
Cells were grown in large 15cm-diameter cell culture dishes to 80% 
confluence and then serum-starved for 24 h. Proteins from two biological 
replicates were extracted from the cells using urea lysis buffer (20 mM HEPES pH 
8.0, 9 M urea, 1 mM sodium orthovanadate, 2.5 mM sodium pyrophosphate, 1 
mM b-glycerophosphate). After 10 minutes on ice, cells were sonicated using 3 
pulses at 30 seconds each, with 2 minutes incubation on ice between pulses. 
After centrifugation at 20 000g for 20 min, lysates were reduced with 4.5mM 
dithiothreitol for 20 min at 60°C. Samples were then alkylated in the dark at room 
temperature for 15 min using carboxo-amidomethylation that contained 10 mM 
iodoacetamide. Lysates were tryptically digested overnight at room temperature in 
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a solution of HEPES and trypsin TPCK solution (Worthington Biochemical) to final 
concentrations of 20 mM and 10 μg/mL, respectively. Peptides were then desalted 
with Sep-Pak C18 columns (Waters Corp) and freeze-dried. Peptides were 
resuspended in an Immunnoaffinity Purification (IAP) buffer (50mM MOPS, pH 
7.2, 10 mM sodium phosphate, 50 mM NaCl), prior to the addition of P-Tyr-100 
mouse monoclonal antibody beads (Cell Signaling). Samples were rotated at 4°C 
overnight, and the beads washed thrice with IAP buffer and water. Trifluoroacetic 
acid (0.15%; TFA) was used to elute the bound peptides, which were then further 
purified using ZipTip C18 (Millipore Corp). 
After the peptides had been resuspended in acetonitrile (3%) containing 
0.1% TFA, they were loaded onto Protein ID #2 chip (Agilent; 40 nL enrichment 
column, 75 μm x 150 mm analytical column). LC-MS/MS analysis was performed 
in duplicate with Agilent’s 6340 Ion trap System with electron transfer dissociation 
(ETD) capability, where fragmentation alternated between collision induced 
dissociation and ETD modes. Four peptides were chosen per scan that had at 
least a double charge. Two biological repeats were performed. For specific run 
conditions, we followed the protocol of Chumbalkar et al., 2011. 
 
 
 
Peptide Identification and Quantification 
 
Initially the MS/MS spectra were extracted using Bruker CompassXport 
(http://www.bruker.com) which created *.mzxml files, which were later converted 
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to *.mgf files using Trans-Proteomic Pipeline (Seattle Proteome Center; 
http://www.proteomecenter.org/software.php). Database searches of the human 
subset of Swiss-Prot database’s proteins was performed using Mascot search 
engine version 2.3.02 (http://www.matrixscience.com). Manual inspection of the 
spectra was performed to assign phosphorylation sites. Based on retention time, 
Ideal-Q (Tsou et al., 2010) software aligned the runs. Next, the peak areas were 
calculated manually for all identified phosphopeptides, and the data normalized to 
the run’s total ion current. Then we calculated individual mean peak areas for the 
phosphopeptides. For more detailed information, we followed the protocol of 
Chumbalkar et al., 2011. 
 
 
TCGA Analysis 
 
Level 3 gene expression data (Agilent 244K Custom Gene Expression chip 
platform; AgilentG4502A_07) was downloaded from the TCGA Data Portal 
(http://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp) on 07/15/11 to examine HGF 
and c-Met mRNA expression in 495 GBMs.  The downloaded data was 
represented as log10 ratios to Universal Human Reference RNA (Stratagene). 
Spearman correlation (two-tailed, 95% CI) calculated the Spearman correlation 
coefficient between c-Met and HGF expression in GBM.  For GBM subtype 
determination, ‘Verhaak determined’ data made use of the subtype calls that can 
be found in the supplementary data from Verhaak et al., 2010.  For ‘Calculated 
Verhaak’ or ‘Calculated Phillips’ datasets, we downloaded the gene lists that were 
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defined by the authors for the various GBM subtypes (Phillips et al., 2006; 
Verhaak et al., 2010). For each tumor, expression values for genes that defined 
each GBM subclass were averaged to derive a metagene score per each of the 
four Verhaak GBM subtypes (mesenchymal, proneural, neural, and classical), and 
for each of the three Phillips GBM subtypes (mesenchymal, proliferative, and 
proneural).  Metagene scores were converted to z-scores (assume metagene 
score normal distribution, and set all scores to mean = 0 and standard deviation = 
1) so that metagene scores could be compared. A GBM subtype was then 
assigned to a tumor based on the metagene score with the highest value. The use 
of metagenes in statistics has previously been described by Colman et al., 2010. 
Data validity was verified in an independent gene expression data set 
(n=180) from the REpository for Molecular BRAin Neoplasia DaTa 
(REMBRANDT; http://caintegrator-info.nci.nih.gov/rembrandt) that used the 
Human Genome U133 Plus 2.0 Array; gene expression data normalized to pooled 
normal brain expression. Data were processed using a robust multiarray average 
(RMA) algorithm with quantile normalization, using R (R Development Core Team, 
2009) and Bioconductor (Gentleman et al., 2004) and a custom CDF (Sandberg 
and Larsson, 2007). GBM subtype calls were performed as was previously 
described in the ‘Calculated Verhaak’ method. 
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Statistical Analysis 
 
GraphPad Prism 5.03 software was used to determine significance of most 
experiments. Specific statistical tests are described in the figure legends. All t-
tests and the Spearman correlation test were two-tailed. 
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CHAPTER 3 
 
RESULTS 
 
C-MET MODULATES HGF EXPRESSION, COLONY FORMATION, 
AND TUMORIGENICITY OF GBM CELLS 
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Coexpression of c-Met and HGF in GBM 
 
There have been reports that c-Met and HGF mRNA are often coexpressed 
in GBM (Beroukhim et al., 2007; Moriyama et al., 1998), prompting us to analyze 
the wealth of new data now available in the TCGA database. The TCGA database 
(http://tcga-data.nci.nih.gov/tcga/findArchives.htm) was established to generate a 
comprehensive archive of various genetic aberrations that occur in cancer, with 
their initial focus on GBM (Verhaak et al., 2010). The TCGA database catalogs 
DNA, mRNA, microRNA and DNA methylation profiles of GBM tumors (Sulman 
and Aldape, 2011; The Cancer Genome Atlas Research Network, 2008). We 
analyzed the coexpression of c-Met and HGF in the TCGA expression data using 
the Agilent (level 3; processed) platform. In total 495 GBM tumors were analyzed 
for their c-Met and HGF expression. We found that c-Met and HGF mRNA 
expression correlated significantly in GBM (Figure 4; Spearman correlation; r = 
0.5199, P < 0.0001), suggesting that the two proteins are coregulated. 
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Figure 4.  HGF and c-Met mRNA expression correlates in GBM.  TCGA 
mRNA expression data for HGF and c-Met were correlated in 495 GBM tumors 
using Spearman correlation (r = 0.5199; P<0.0001; linear regression is shown; 
TCGA level 3 expression data for the Agilent platform was downloaded as log10 
ratios to Universal Human Reference RNA; Dr. Brian Vaillant, Dr. Howard 
Colman’s former post-doctoral fellow, performed this analysis). 
 
 
 
c-Met Modulates HGF Expression 
 
c-Met and HGF are both located on the same arm of chromosome 7 (7q31 
and 7q21, respectively; Beau-Faller et al., 2008). Even though trisomy of 
chromosome 7 is a frequent occurrence in GBM (Lopez-Gines et al., 2005; 
Piccirillo et al., 2009), our data shows a broad dynamic range of expression for 
HGF and c-Met that is not easily accounted for by the addition of a single gene 
copy. One possible mechanism that may explain their coordinated regulation may 
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be due to the formation of a positive regulatory loop. It has been shown previously 
that c-Met’s expression can be induced by HGF stimulation (8 h) in GBM cells 
(Abounader et al., 2001). We therefore hypothesized that HGF expression may 
positively be modulated by its own receptor.  
Immortalized human cancer cells have been used for many decades as 
useful biological tools with which to expand our knowledge of cancer biology. 
Certain tumor cells are largely reliant on specific oncogenes that they express for 
the generation of prosurvival signals (Pillay et al., 2009). Cell lines that coexpress 
HGF and c-Met are considered c-Met-dependent cell lines (Beroukhim et al., 
2007), and are dependent on this signaling axis for proliferation and survival 
(Martens et al., 2006; Pillay et al., 2009). U87 is one such c-Met-dependent GBM 
cell line (Pillay et al., 2009). Therefore, we confirmed that c-Met could be acutely 
activated by recombinant human HGF (rhHGF) in U87 cells (Figure 5), and that 
HGF was being secreted by this cell line (Figure 6). c-Met was activated 
(Y1234/Y1235) within 5 minutes of HGF stimulation in U87 cells, with strongest 
activity seen between 15 and 45 minutes of treatment (Figure 5). AKT 
phosphorylation at S473 was used to assess PI3K pathway activation, which 
occurred within 30 minutes of HGF stimulation.  
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Figure 5. c-Met is acutely activated by HGF in U87 cells. Western blots 
measured c-Met activation (Y1234/Y1235), and p-AKT (S473), via HGF 
stimulation (50 ng/mL) of U87 cells for the indicated amounts of time. EGF 
stimulation (10 ng/mL) of U87 cells was used as a positive control. Vinculin was 
used as a loading control. 
 
 
 
Using ELISA, we did not detect HGF secretion from U251, a GBM cell line 
known not to produce HGF (Beroukhim et al., 2007). Conversely, HGF secretion 
was detected in conditioned media from U87 cells (Figure 6). 
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Figure 6. HGF is secreted by U87 cells. ELISA quantification of HGF in CM 
from U87 and U251 GBM cells. Cells were cultured in serum-free conditions for 24 
h (triplicate serial dilutions analyzed above background; Dr. Kristen Hill, Dr. Lisa 
Elferink’s former graduate student, UTMB, performed the analysis). 
 
 
 
 Based on these findings we used the U87 cell line to investigate the effect 
of c-Met abrogation on the expression of HGF. We stably expressed lentiviral 
short hairpin RNA (shRNA) constructs that targeted c-Met in U87 cells, and 
established clonal populations from the two most effective shRNA constructs by 
limiting dilution (data not shown).  As measured by quantitative RT-PCR (qRT-
PCR), knockdown of c-Met decreased HGF expression at the mRNA level in U87 
cells (Figure 7). 
 
 
50 
 
 
 
Figure 7. HGF mRNA expression is dependent on c-Met expression. qRT-
PCR analysis of HGF mRNA expression in clonal populations of U87 cells that 
expressed different c-Met shRNA targeting constructs. Cells were cultured in 
media containing 10% FBS (** = P<0.01; Student’s t-test compared with sh-
control; n = 3±SEM; samples were analyzed at least in duplicate per experiment). 
 
 
 
mRNA levels are not necessarily comparable to protein amounts within a 
cell, therefore it was important for us to investigate what effect c-Met silencing 
would have on HGF protein levels. We examined U87 c-Met knockdown cells 
using western blotting techniques and confirmed that HGF protein levels 
decreased with c-Met knockdown (Figure 8). 
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Figure 8. HGF protein expression is dependent on c-Met expression. 
Western blot analysis of HGF protein expression in clonal populations of U87 cells 
that expressed different c-Met shRNA targeting constructs. Protein lysates were 
obtained from cells that were cultured in media containing 10% FBS. 
 
 
 
Given that HGF is a secreted protein that binds and activates the c-Met 
receptor at the cell surface, we performed Enzyme-linked Immunosorbent Assays 
(ELISAs) to analyze HGF amounts that were secreted into the CM from U87 cells 
with c-Met knockdown. We found that HGF secretion was attenuated by c-Met 
knockdown in U87 cells (Figure 9A). Western blot analysis revealed that levels of 
secreted HGF were not proportional to the degree of c-Met knockdown (Figure 
9B). This suggested that threshold levels of c-Met expression may modulate the 
expression of HGF in this cell line. Cumulatively, our data revealed that the 
 
 
52 
 
expression of c-Met is an important component necessary for the production and 
secretion of HGF in U87 GBM cells. 
 
 
 
 
 
Figure 9. HGF secretion decreases with c-Met knockdown in U87 cells. (A) 
ELISA quantification of HGF in CM from U87 sh-c-Met knockdown clones that 
represent two different shRNA targeting sequences, A and B (** = P<0.01; one-
way ANOVA compared with U87 sh-control cells; Dunnett’s multiple comparison 
test; triplicate serial dilutions above background analyzed per experiment; n = 2; 
Dr. Kristen Hill, Dr. Lisa Elferink’s former graduate student, UTMB, performed 
these analyses). Cells were cultured in serum-free conditions. (B) Western 
analysis showing c-Met knockdown in cell lines that were represented in A. Cells 
were cultured in media containing 10% FBS. 
 
 
 
Interestingly, using bright field microscopy we observed that the cellular 
morphology of U87 cells changed with silencing of c-Met (Figure 10). The U87 
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parental or sh-control cells had the appearance of being scattered, spindle-
shaped, mesenchymal-like cells, whereas the U87 cells with c-Met knockdown 
appeared epithelial-like with loss of the scattering phenotype. HGF, also known as 
scatter factor (Birchmeier et al., 2003), typically leads to the dissociation and 
dispersion of epithelial cells (Maulik et al., 2002). Given our data showing that the 
expression of HGF, or scatter factor, is lost with c-Met knockdown (Figures 7-9), it 
is tempting to speculate that the altered morphology observed with c-Met 
knockdown may in part be due to decreased HGF expression in these cells. 
 
 
 
Figure 10. Cellular morphology changes with c-Met knockdown in U87 
cells. Bright field microscopy of U87, U87 sh-control, U87 sh-c-Met #A and U87 
sh-c-Met #B polyclonal populations. 
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 We next examined whether the kinase function of c-Met was important for 
this phenotypic change. We generated and overexpressed kinase-deficient c-Met 
mutants (Y1234F and Y1235F), wt-c-Met, and oncogenic c-Met mutants [P991S 
(Lee et al., 2000); Y1003F (Abella et al., 2005)], in U87 cells (Figure 11A). Bright 
field microscopy revealed that the U87 cells expressing kinase-deficient mutants 
lost their spindle, mesenchymal-like, appearance and were transformed into 
cuboidal, epithelial-like, shaped cells (Figure 11B). These results suggest that 
Y1234 and Y1235 of c-Met are necessary to maintain the mesenchymal-like 
morphology of U87 GBM cells. 
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Figure 11. Cellular morphology alters with overexpression of kinase-
impaired c-Met mutants in U87 cells. (A) Western blot analysis of U87 cells that 
overexpressed an empty vector control (pMSCV-puro), wt c-Met, c-Met P991S, c-
Met Y1003F, c-Met Y1234F, and Y1235F. (B) Bright field microscopy of all cell 
lines represented in (A). 
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Next, we asked whether the c-Met signal was required for HGF production. 
To answer this question, we treated U87 cells with SU11274. This compound 
selectively targets the c-Met receptor by a factor of 50 when compared with other 
receptor tyrosine kinases (Peruzzi and Bottaro, 2006). The treatment of U87 GBM 
cells with SU11274 decreased HGF mRNA (Figure 12A) and protein (Figure 12B) 
amounts. 
 
 
   
Figure 12. c-Met inhibition reduces HGF mRNA and protein amounts in 
U87 cells. (A) HGF qRT-PCR of U87 cells treated with 10 µM SU11274 for 16h; 
media contained 10% FBS (* = P<0.05; Student’s t-test compared with 0.1% 
DMSO control; n = 4±SEM; at least duplicate samples per experiment). (B) 
Western blot analysis of HGF and c-Met activity levels (Y1234/Y1235) in U87 cells 
after 0.1% DMSO or 10 μM SU11274 treatment for 16h; media contained 10% 
FBS. 
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We wanted to determine if HGF expression would also be suppressed in a 
cell line other than U87 when c-Met’s tyrosine kinase activity was inhibited. The 
GBM cell line LN18 produces both c-Met and HGF, and is therefore considered c-
Met-dependent (Beroukhim et al., 2007). We treated LN18 cells with SU11274 to 
inhibit c-Met activity, and analyzed HGF content by qRT-PCR and by western 
analysis. We found that LN18 cells responded analogously to that of U87 cells, 
where HGF mRNA (Figure 13A) and protein (Figure 13B) amounts decreased with 
c-Met inhibition. 
 
 
 
 
Figure 13. HGF mRNA expression and protein levels decrease with c-Met 
knockdown in LN18 cells. (A) HGF qRT-PCR of LN18 cells treated with 10 µM 
SU11274 for 16h; media contained 10% FBS (** = P<0.01; Student’s t-test 
compared with 0.1% DMSO control; n = 4±SEM; at least duplicate samples per 
experiment). (B) Western blot analysis of HGF and c-Met activity levels 
(Y1234/Y1235) in LN18 cells after 0.1% DMSO or 10 μM SU11274 treatment for 
16h; media contained 10% FBS. 
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Taken together, our results suggest that the coregulation of HGF and c-Met 
occurs primarily at the mRNA level, and that the activity of c-Met is required for 
HGF expression in GBM cells. 
 
 
 
c-Met is Required for Anchorage-independent Growth of U87 
Cells 
 
Next, we characterized the biological implications of shRNA-mediated 
silencing of c-Met in U87 cells. Initially, we started our investigations by 
performing anchorage-independent growth assays, since it is a quick and simple 
method to perform, yet models some important aspects of tumorigenicity in vivo, 
such as cancer cell proliferation without firm attachment. We found that the 
number of colonies (Figure 14A), and the size of the colonies (Figure 14B), 
decreased significantly with reduced c-Met expression in U87 cells.  
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Figure 14. Anchorage-independent growth of U87 cells with c-Met 
knockdown. (A) Colony formation assays determined the number of colonies 
produced by U87 sh-control cells when compared with U87 shRNA-c-Met clones 
(different targeting constructs) after growth for 14 days (* = P<0.05; Student’s t-
test; n = 3±SEM; at least triplicate samples per experiment). (B) Representative 
images of colony formation on day 14. 
 
 
 
To understand the mechanisms that may contribute to the decreased 
anchorage-independent growth of U87 sh-c-Met cells, we performed WST-1 
assays that measured the metabolic activity of viable cells. Even though all of the 
cell lines were plated on the same day using equal cell numbers, and grown under 
the same conditions, the metabolic activities of the U87 sh-c-Met clones were less 
than that observed in the U87 sh-control cells after 3 days of growth (Figure 15A). 
Therefore, the total number of viable cells may have decreased over time with c-
Met knockdown when compared with the scrambled sh-control cell line. 
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Although it’s not definitive proof of apoptosis, altered BCL-XL expression 
levels suggest that changes in cell viability have occurred (Boise et al., 1993, 
Nagane et al., 1996). Using qRT-PCR, we showed that BCL-XL expression 
decreased with SU11274 treatment of U87 cells (Figure 15B).  
 
 
 
Figure 15. c-Met suppression alters biological characteristics of U87 cells. 
(A) WST-1 assays measured the metabolic activities of U87 sh-control cells, and 
U87 sh-c-Met clones (different c-Met sh-RNA targeting constructs) after 72 h in 
culture (± SEM); media contained 10% FBS (B) BCL-XL qRT-PCR of U87 cells 
treated with 0.1% DMSO or 10 µM SU11274 for 16h (± SEM); media contained 
10% FBS. 
 
 
Taken together, the decrease in anchorage-independent growth of U87 sh-
c-Met cells may be due to increased cell death. However, in order to support this 
conclusion, additional experiments should be performed that would measure the 
degree of apoptosis directly. 
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Silencing c-Met Suppresses the Tumorigenicity of Intracranial 
GBM Xenografts 
 
We examined the tumorigenicity of U87 cells with c-Met knockdown in vivo 
by measuring the survival of nude mice that had been intracranially injected with 
these cells (Figure 16). The median survival of mice in the U87 sh-control group 
was 16 days. After 65 days, we sacrificed the mice in the U87 sh-c-Met groups 
since they did not show any neurological symptoms of tumor burden. We 
confirmed the absence of tumors in two mouse brains per c-Met knockdown cell 
line tested by microscopic examination of H&E stained brain sections.  
 
 
Figure 16. c-Met 
silencing decreases the 
tumorigenicity of U87 
xenografts. Nude mice were 
injected intracranially with 
2x105 U87 sh-control or 
2x105 U87 sh-c-Met clonal 
cells and their survival was 
documented over 65 days. 
The median survival for each 
group of mice and the 
significant differences 
between them are shown 
(Log-rank test; P<0.0001; 
U87 sh-control versus U87 
sh-c-Met clones).  
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Taken together, our data suggest that the expression of c-Met is an 
important component needed to maintain anchorage-independent growth and 
tumorigenicity of U87 GBM cells. 
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CHAPTER 4 
  
RESULTS 
 
∆EGFR REGULATES HGF EXPRESSION VIA C-MET ACTIVATION 
AND REQUIRES C-MET FOR ONCOGENICITY 
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∆EGFR Induces the Expression of HGF via c-Met Activation 
 
Using an open mass spectrometry-based approach to examining the 
∆EGFR signal in GBM cells, our laboratory (Chumbalkar et al., 2011), and an 
independent group of investigators (Huang et al., 2007), found that the intensity of 
the c-Met phosphopeptide Y1234 increased in response to the ∆EGFR signal in 
GBM cells. Since the activity of c-Met is an important component necessary for 
the production of HGF in c-Met-dependent GBM cells, we asked whether ∆EGFR 
could increase HGF expression via c-Met activation. Using qRT-PCR, we found 
that HGF mRNA amounts tripled with ∆EGFR expression in U87 cells (Figure 17).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. ∆EGFR increases the mRNA expression of HGF. HGF mRNA 
amounts were measured by qRT-PCR in U87 cells and in those that 
overexpressed ∆EGFR (cells were cultured in DMEM media containing 10% FBS; 
* = P<0.05; Student’s t-test; n = 3±SEM; samples were analyzed at least in 
duplicate per experiment). 
 
 
65 
 
We performed western blot analysis to confirm that the protein expression 
of HGF increased with ∆EGFR expression (Figure 18). To confirm that increased 
HGF expression correlates with enhanced c-Met signaling, we 
immunoprecipitated c-Met and performed western blot analysis. As shown in 
Figure 18, c-Met activity was enhanced in the presence of constitutively active 
∆EGFR. It was necessary to immunoprecipitate c-Met due to a strong cross-
reactivity of the pc-Met Y1234/Y1235 antibody with phosphorylated ∆EGFR; c-Met 
and ∆EGFR are approximately the same size when analyzed by western blot. 
 
 
 
Figure 18. ∆EGFR increases the protein expression of HGF. Western blots 
measured HGF protein expression and p-c-Met (Y1234/Y1235) amounts after c-
Met was immunoprecipitated from lysates that were prepared from U87 and U87 
∆EGFR cells. Cells were cultured for 20 h in media containing 1% serum. 
 
 
Madin-Darby Canine Kidney (MDCK) cells are acutely sensitive to HGF 
stimulation, and respond rapidly by eliciting c-Met-dependent biological programs 
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(Cao et al., 2001; Christensen et al., 2003). Therefore, we used MDCK cells to 
determine if HGF was being secreted from U87 cells that expressed ∆EGFR, and 
if the secreted HGF was functional. Upon stimulation of MDCK cells with CM from 
U87 ∆EGFR cells, we found that c-Met was acutely activated (Y1234/Y1235) in a 
time-dependent manner (Figure 19). This level of c-Met activation was also 
observed when MDCK cells were acutely stimulated with rhHGF. In order to prove 
that HGF from U87 ∆EGFR CM was responsible for c-Met activation in MDCK 
cells, we pre-neutralized HGF in an aliquot of the CM with an anti-HGF antibody. 
This resulted in attenuation of the c-Met signal in MDCK cells when compared 
with the signal generated by rhHGF stimulation or with untreated U87 ∆EGFR CM. 
These data suggested that HGF was being secreted by U87 ∆EGFR cells, and 
that the secreted HGF was functional. 
 
 
 
Figure 19.  Functional HGF is secreted by ∆EGFR-expressing GBM cells. 
CM from U87 ∆EGFR cells was transferred to MDCK cells for the indicated 
amounts of time (min).  c-Met activation was detected by western blot. MDCK 
cells were also stimulated for 15 min with rhHGF (50 ng/mL), or media (-), or with 
CM that had been pre-neutralized for 2 h with an anti-HGF antibody. Cells were 
cultured in media containing 1% FBS. 
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Inhibition of ∆EGFR suppresses HGF expression 
 
The kinase-dependent function of the ∆EGFR is responsible for enhanced 
c-Met activation in GBM cells (Pillay et al., 2009). We have shown that c-Met is 
responsive to the ∆EGFR signal (Figure 18; Chumbalkar et al., 2011), and that 
HGF production increases with ∆EGFR overexpression (Figures 17-18). 
Therefore, we tested the hypothesis that ∆EGFR’s kinase activity regulates HGF 
expression. We inhibited the kinase activity of ∆EGFR with AG1478, a specific 
EGFR TKI that preferentially antagonizes the ∆EGFR (Huang et al., 2007), and 
analyzed HGF mRNA expression by qRT-PCR. This analysis revealed that HGF 
mRNA amounts decreased with inhibition of the ∆EGFR signal (Figure 20). As 
expected, HGF mRNA expression also decreased with SU11274 treatment of U87 
∆EGFR cells. Treatment of U87 ∆EGFR cells with either SU11274 or AG1478 
suppressed the expression of HGF to a similar extent. The dual inhibition of U87 
∆EGFR cells with SU11274 and AG1478 did not result in greater attenuation of 
HGF mRNA expression to that of either agent alone.  These results suggest that 
c-Met and ∆EGFR regulates HGF mRNA expression through the same pathway.  
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Figure 20. HGF mRNA expression decreases with inhibition of ∆EGFR.  
HGF mRNA amounts were measured by qRT-PCR of U87 ∆EGFR cells that were 
either untreated, or treated with 0.1% DMSO, 10 µM AG1478, 10 µM SU11274, or 
with a combination of 10 µM AG1478 and 10 µM SU11274. Cells were treated for 
16 h in media containing 10% FBS (** = P<0.01; Student’s t-test when compared 
with the DMSO-treated control; n = 3±SEM; samples were analyzed at least in 
duplicate per experiment). 
 
 
We performed western blot analysis in order to confirm that the treatment 
of U87 ∆EGFR cells with SU11274 and AG1478 effectively inhibited the kinase 
activities of c-Met and ∆EGFR, as well as the protein expression of HGF. 
Surprisingly, AG1478 treatment of U87 ∆EGFR cells did not attenuate HGF 
protein expression and c-Met phosphorylation (Y1234/Y1235) to the same extent 
as SU11274 (Figure 21). The inhibitor-dependent decrease in c-Met 
phosphorylation did however correlate with the amount of HGF that was being 
produced at the protein level. Given that HGF mRNA and protein amounts are not 
inhibited to the same extent following the treatment of U87 ∆EGFR cells with 
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AG1478 (Figure 20 and Figure 21), our results suggest that HGF may also be 
post-transcriptionally or post-translationally regulated in U87 ∆EGFR-expressing 
cells. However, our data provide solid support for the existence of a positive feed-
forward relationship between the degree of c-Met activation and the level of HGF 
protein expression. 
 
 
Figure 21. HGF protein 
expression is attenuated with 
inhibition of ∆EGFR.  HGF, pc-Met 
(Y1234/Y1235), and pEGFR 
(Y1173) levels were detected by 
western blot analysis of U87 
∆EGFR cells that were either 
untreated or were treated with 
0.1% DMSO, 10 µM AG1478, 10 
µM SU11274, or a combination of 
10 µM AG1478 and 10 µM 
SU11274. pc-Met (Y1234/Y1235) 
amounts were detected by western 
blot following c-Met 
immunoprecipitation. Cells were 
treated for 16 h in media 
containing 10% FBS. 
 
 
 
c-Met is Required by ∆EGFR for HGF Production, Anchorage-
Independent Growth, and Tumorigenicity of GBM Cells 
 
We then asked whether HGF expression could be maintained by ∆EGFR in 
the absence of c-Met. To answer this question, we overexpressed ∆EGFR in U87 
sh-c-Met clones and examined HGF mRNA by qRT-PCR. We found that ∆EGFR 
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did not sustain HGF production when c-Met levels were silenced (Figure 22A). 
HGF protein levels were then evaluated in U87 ∆EGFR sh-c-Met cells by western 
blot analysis, and we found that the protein expression of HGF was attenuated 
with c-Met knockdown in these cells (Figure 22B). As with previous experiments 
where U87 cells were engineered to overexpress ∆EGFR (Figure 20 and Figure 
21), there appears to be an uncoupling in regulation of HGF at the mRNA and 
protein levels. Therefore, these data suggest that HGF may additionally be 
controlled post-transcriptionally or post-translationally by the ∆EGFR signal. 
Cumulatively, our findings suggest that ∆EGFR requires the presence of c-Met to 
maintain enhanced levels of HGF expression in U87 cells. 
 
 
 
Figure 22. c-Met is required by ∆EGFR to maintain HGF expression. (A) 
HGF mRNA amounts were measure by qRT-PCR in U87 sh-c-Met clonal 
populations (different c-Met shRNAs) that expressed ∆EGFR. Cells were cultured 
in media containing 10% FBS (* = P<0.05; *** = P<0.001; Student’s t-test; n = 3 ± 
SEM; samples were analyzed at least in duplicate per experiment). (B) HGF 
protein levels were measured by western blot analysis in all cells detailed in (A). 
Cells were cultured in media containing 10% FBS. 
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We determined whether ΔEGFR was capable of overcoming the 
suppression in anchorage-independent growth that we have previously seen with 
c-Met knockdown in U87 cells (Figure 14). Our results indicated that ∆EGFR 
required c-Met to exert its stimulation of anchorage-independent growth of U87 
cells, as it was unable to rescue the loss in colony formation of U87 cells with c-
Met knockdown (Figure 23A). Even though the number of colonies for the U87 cell 
line were comparable to the number of colonies of the U87 ΔEGFR cell line 
(Figure 14A and Figure 23A), by visual examination we found that the colonies 
produced by the latter cell line were far larger in diameter and volume compared 
with the growth of parental cells (Figure 14B, and Figure 23B). 
 
 
 
Figure 23. In vitro colony formation of U87 ΔEGFR-expressing cells with c-
Met knockdown. (A) Anchorage-independent growth assays determined the 
number of U87 sh-control ΔEGFR colonies compared with U87 sh-c-Met #A2 
ΔEGFR and U87 sh-c-Met #B2 ΔEGFR colonies after 14 days growth (* = P<0.05; 
** = P<0.01; Student’s t-test; n = 3±SEM; at least triplicate samples per 
experiment). (B) Representative images of anchorage-independent growth of cell 
lines described in (A) on day 14. 
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In order to determine if the diminished anchorage-independent growth of 
U87 sh-c-Met ΔEGFR cells may partly be due to changes in cell viability and BCL-
XL expression, we performed WST-1 and qRT-PCR assays, respectively (Figure 
24A and Figure 24B). We found that with c-Met knockdown, U87 ΔEGFR cells 
were unable to maintain a high level of metabolic activity (Figure 24A), and that 
BCL-XL expression decreased with c-Met inhibition in these cells (Figure 24B). 
These results indicated that the total number of cells, and BCL-XL expression, 
decreased with c-Met suppression in U87 ΔEGFR cells. These data suggested 
that c-Met plays an important role in the viability of U87 cells even when ΔEGFR 
is expressed.  
 
 
 
Figure 24. Biological properties of U87 ΔEGFR cells are altered with c-Met 
knockdown. (A) WST-1 assays measured changes in metabolic activity (± SEM) 
of U87 ΔEGFR cells with c-Met knockdown (U87 sh-c-Met #A2 ΔEGFR cells and 
U87 sh-c-Met #B2 ΔEGFR cells) after 72 h growth in media containing 10% FBS 
(B) qRT-PCR quantified BCL-XL mRNA expression (±SEM) in U87 ΔEGFR cells 
that were treated with 0.1% DMSO or 10 µM SU11274 for 16h in media containing 
10% FBS. 
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The ∆EGFR is a potent oncogene that confers enhanced tumorigenicity to 
U87 cells in vivo (Huang et al., 1997; Nishikawa et al., 1994). Our data therefore 
raised the question of whether ∆EGFR was capable of overcoming the reduced 
tumorigenicity that we’ve found to be associated with c-Met knockdown in U87 
cells (Figure 16). Hence, we measured the survival of nude mice that had been 
intracranially injected with either U87 sh-c-Met cells overexpressing ∆EGFR, with 
U87 sh-control cells, or with U87 sh-control cells that overexpressed ∆EGFR over 
a period of 65 days (Figure 25).  
 
 
 
 
Figure 25.  c-Met is required by ∆EGFR to enhance the tumorigenicity of 
U87 cells. Over a period of 65 days, survival curves were generated from mice 
that had been intracranially injected with 2x105 U87 sh-control ± ΔEGFR, U87 sh-
c-Met #A2 ΔEGFR, or with U87 sh-c-Met #B2 ΔEGFR cells (Log-rank test; 
P<0.0001 when compared with the U87 sh-control group; median survival per 
group of mice was recorded). 
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Compared with the U87 sh-control group, ∆EGFR overexpression 
significantly augmented the tumorigenicity of U87 cells in vivo as expected from 
many prior studies. Surprisingly, mice that received U87 sh-c-Met (#A2 or #B2 
clones) cells that overexpressed ∆EGFR did not become moribund within 65 days 
of intracranial injection. The absence of tumors in these mice was verified in H&E 
stained serial sections by visual examination under a microscope. Cumulatively, 
these data suggest that c-Met is an important component necessary for the 
maintenance of tumorigenicity of c-Met-dependent GBM cells, regardless of the 
∆EGFR signal. 
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CHAPTER 5 
  
RESULTS 
 
STAT3 PARTIALLY MODULATES HGF EXPRESSION IN 
RESPONSE TO THE C-MET SIGNAL IN ∆EGFR-EXPRESSING  
GBM CELLS 
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STAT3 is a Key Node Regulating HGF Expression in Response to 
the c-Met Signal 
 
We used an unbiased shotgun phosphoproteomics-based approach to 
further understand the signaling events that lead to changes in HGF expression 
upon modification of the c-Met signal in U87 and U87 ΔEGFR cells. We chose to 
enrich for phosphotyrosine peptides so as to provide an accurate snapshot of 
signaling events that were initiated by c-Met and ΔEGFR. By doing this, we also 
increased the probability of being able to detect all phosphotyrosine modifications 
present on low-abundance proteins, and phosphotyrosine-related signaling events 
occurring in a milieu of unphosphorylated, serine-phosphorylated, and threonine-
phosphorylated proteins (Macek et al., 2009). Specifically, after recovering 
tyrosine-phosphorylated peptides from tryptically digested lysates of U87 sh-
control, U87 sh-control ∆EGFR, U87 sh-c-Met #B2, and U87 sh-c-Met #B2 
∆EGFR cells, we performed LC-MS/MS (see Figure 26 for a schematic of the 
methodology that was performed). 
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Figure 26. Schematic of mass spectrometry experiments. Two biological 
repeats per cell line (U87 sh-control, U87 sh-control ∆EGFR, U87 sh-c-Met #B2, 
and U87 sh-c-Met #B2 ∆EGFR) were processed and analyzed in duplicate by 
mass spectroscopy (Dr. Vaibhav Chumbalkar, Dr. Oliver Bögler’s former post-
doctoral fellow, performed all mass spectrometry experiments). 
 
 
 
An equal volume of lysate from each cell line that was processed for 
PhosphoScan was analyzed by western to confirm their identity (Figure 27). 
These data also showed that comparable amounts of protein, as assessed by 
actin levels, were present in each sample within a biological replicate set. 
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Figure 27. Confirmation of sample identities that were processed for 
PhosphoScan analysis. Western blot analysis of lysates that were used in mass 
spectrometry experiments. 
 
 
We identified 112 peptides that were tyrosine-phosphorylated, which 
corresponded with 82 proteins. Table 5 provides a complete list of all 
phosphotyrosine-modified peptides that were identified in our screen.  
 
Peptide  
Index 
Swissprot ID  
(Human) 
m/z Charge Modification site (s) 
1157 ABI1 765.5856 3 TLEPVKPPTVPNDyMTSPAR 
1233 ABI1 966.5225 3 NTPyKTLEPVKPPTVPNDYMTSPAR 
651 ABL2/ABL1 506.6402 3 LMTGDTyTAHAGAK 
1063 ACK1 802.5335 3 KPTyDPVSEDQDPLSSDFKR 
1288 ACK1 764.2574 3 VSSTHyYLLPERPSYLER 
954 ACTN1 370.8297 3 sIVNyKPK 
542 ACTS 802.4712 3 DLYANNVMSGGtTMyPGIADR 
1764 ANKL2 760.7147 2 yVVDLYLNTPDK 
919 ANXA2 963.2993 2 LSLEGDHSTPPSAyGSVK 
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927 ANXA2 642.7831 3 LSLEGDHSTPPSAyGSVK 
1653 ANXA2 771.2139 2 SYSPyDMLESIR 
1339 BCAR1 656.7297 3 HLLAPGPQDIyDVPPVR 
849 CALR 908.7309 3 GLQTSQDARFyALSAsFEPFSNK 
2216 CCNL2 415.302 3 ERSRsyER 
883 CDK1 673.6172 2 IGEGtyGVVYK 
863 CDK2 633.7101 2 IGEGTyGVVYK 
893 CDK3 634.1149 2 IGEGTYGVVyK 
1338 CILP2 339.2904 3 VRAyANDK 
524 CML1 838.6844 3 LVNALSEDTGHSSyPSHRSFTK 
695 COF1 624.6044 3 HELQANCyEEVKDR 
1779 CSKI2 817.7112 3 NTyNQTALDIVNQFTTSQASR 
634 CSKP 821.7138 3 GSItFKIVPSyRTQSSSCER 
1359 DCBD2 694.248 3 ATGNQPPPLVGTyNTLLSR 
1487 DCBD2 977.9353 3 AGKPGLPAPDELVyQVPQSTQEVSGAGR 
1942 DCBD2 1012.035 3 EVTTVLQADSAEyAQPLVGGIVGTLHQR 
1013 DYH6 690.5724 3 LVMTCAAFITMNPGyAGR 
873 DYH7 844.2557 3 NMEKANSLYVIKLsEPDyVR 
728 DYR1A 576.1992 2 IYQyIQSR 
1372 EF1A1 698.1473 2 EHALLAyTLGVK 
678 EGFR 645.9033 2 GSTAENAEyLR 
1347 EGFR 773.0428 3 GSHQISLDNPDyQQDFFPK 
1605 ENOA 943.5977 2 AAVPSGASTGIyEALELR 
1608 ENOA 628.9258 3 AAVPSGASTGIyEALELR 
2191 ENOA 1023.007 3 SFIKDyPVVSIEDPFDQDDWGAWQK 
1903 ENOG 772.2438 3 AGyTEKIVIGMDVAASEFYR 
2304 EVPL 367.7344 3 SQYRDLLK 
1548 FKBP4 763.0661 2 EKKLyANMFER 
1198 GCYA3 404.0985 3 INVsPTTy]R 
1552 GDE 547.7351 3 EAMsAyNSHEEGR 
1624 GDE 732.2042 2 FsCDVAEGKyK 
770 GRLF1 1014.507 2 NEEENIySVPHDSTQGK 
771 GRLF1 676.6196 3 NEEENIySVPHDSTQGK 
1890 GRLF1 1086.948 3 SVSSSPWLPQDGFDPSDyAEPMDAVVKPR 
808 GSK3A 721.2467 2 GEPNVsyICSR 
842 GSK3A 454.7474 3 GEPNVSyICSR 
841 GSK3A/GSK3B 681.7287 2 GEPNVSyICSR 
681 IMPG1 802.5516 3 LRVCQEAVWEAyRIFLDR 
949 ITB1 652.7658 2 WDTGENPIyK 
2200 ITIH2 502.407 3 LGFyFQsEDIK 
642 ITSN1 423.9775 3 GWFPKsyVK 
2048 K2C1B 708.8024 3 GRSGGGYGSGCGGGGGSyGGsGR 
1737 LDHA 600.2064 2 DQLIyNLLK 
2247 LDHA 885.3657 3 GyTsWAIGLSVADLAESIMKNLR 
1046 LRCC1 612.3049 3 RDTDITSESDyGNRK 
1960 LY75 730.6363 2 yLNNLYKIIPK 
955 M3K8 884.0403 3 ADIySLGATLIHMQTGTPPWVKR 
1083 MK01 742.2217 3 VADPDHDHTGFLTEYyVATR 
1107 MK01 769.2481 3 VADPDHDHTGFLtEYyVATR 
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1135 MK03 751.7668 3 IADPEHDHTGFLTEyVATR 
1153 MK03 778.1629 3 IADPEHDHTGFLtEyVATR 
719 MK14 525.9742 3 HTDDEMTGyVATR 
725 MK14 789.0988 2 HTDDEMTGyVATR 
2217 MLL3 727.2823 2 KEKLyEsQNR 
1534 NP1L2 547.8437 3 yDEPILKLLTDIK 
693 ODPAT 585.316 3 YHGHsMSDPGVSyR 
1830 OR8J1 867.6084 3 MASVFYtLVIPMLNPLIySLR 
1760 OSBL5 760.8906 3 LTRNLLLSGDNELyPLSPGK 
704 PAXI 703.5767 3 FIHQQPQSSsPVyGSSAK 
736 PAXI 677.1365 3 FIHQQPQSSSPVyGSSAK 
802 PAXI 539.0703 3 VGEEEHVySFPNK 
809 PAXI 808.4905 2 VGEEEHVySFPNK 
1410 PRP4B 840.0695 3 LCDFGSASHVADNDITPyLVSR 
1411 PRP4B 1259.978 2 LCDFGSASHVADNDITPyLVSR 
1754 PRRC1 612.3048 3 QMIYsAARAIAGMyK 
981 PTN11 908.8163 2 IQNTGDYyDLYGGEK 
1666 PTPRA 995.5192 2 VVQEYIDAFSDyANFK 
1694 PTPRA 663.9271 3 VVQEYIDAFSDyANFK 
819 PTRF 500.7654 3 KSFTPDHVVyAR 
1629 PUR8 528.9814 3 RAFIITGQtyTR 
1365 RGPD3 491.0598 3 MGSGLNSFyDQR 
741 RHG42 667.865 3 LDTASSNGyQRPGSVVAAK 
1002 RIN1 948.6034 3 EKPAQDPLyDVPNASGGQAGGPQRPGR 
1076 S12A5 847.27 3 GLSLSAARyALLRLEEGPPHtK 
1328 SETB2 386.8967 3 KLPQFKyR 
801 SHB 835.1677 2 GESAGyMEPYEAQR 
1097 SHB 627.6371 3 DKVTIADDySDPFDAK 
1419 SHC1 988.7607 2 ELFDDPSyVNVQNLDK 
730 SMC1B 602.6334 2 yQSLLEELK 
1155 SRC8 746.0805 3 GPVSGTEPEPVySMEAADYR 
2337 SSH1 915.7318 3 sCPNGMEDDAIFGILNKVKPSyK 
895 STA13 502.2786 3 FDQTTRRSPyR 
1968 STAR9 754.4364 3 GTVLSyCETLLEPECSsR 
2345 STAT3 861.73 3 YCRPESQEHPEADPGSAAPyLK 
1822 SYNE1 839.7582 2 AQyHLKIGSsEQR 
574 TEKT4 363.4678 3 yHQAFADR 
810 TITIN 382.0819 3 VGGGEyIELK 
2306 TITIN 404.9394 3 EISTsAKyR 
1163 TLN1 563.3869 2 ALDyYMLR 
1303 TLN1 639.8245 3 TMQFEPSTMVyDACR 
1320 TLN1 958.8162 2 TMQFEPSTMVyDACR 
2183 TLN1 885.3069 3 AVSSAIAQLLGEVAQGNENyAGIAAR 
656 TPP2 859.9542 3 IPKGAGPGCyLAGSLTLsKTELGK 
975 TYK2 534.3826 3 LLAQAEGEPCyIR 
1206 UBP36 993.5783 3 VKCSVCKSVSDtYDPyLDVALEIR 
869 VIME 755.2954 2 SLYASSPGGVyATR 
906 VIME 754.7248 2 SLYASSPGGVyATR 
947 VIME 668.077 2 LGDLyEEEMR 
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Table 5. List of peptides with a phosphotyrosine modification identified by 
mass spectrometry. Peptides identified as being tyrosine phosphorylated by 
PhosphoScan analysis are listed along with their peptide modification(s), charge-
to-mass ratio, charge, and assigned peptide identification number. 
 
 
The mean abundance (signal intensity) of all phosphotyrosine-modified 
peptides that were discovered by mass spectrometry in U87-sh-control, U87 sh-c-
Met #B2, U87 sh-control ∆EGFR, and in U87 sh-c-Met #B2 ∆EGFR cells are listed 
in Table 6.  
 
 
Mean Abundance  
Swissprot ID 
(Human) 
U87 sh-control 
U87 sh-c-Met 
#B2 
U87 sh-control 
ΔEGFR 
U87 sh-c-Met 
#B2 ΔEGFR 
ABI1 1390002.36 557123.89 1490703.14 401405.14 
ABI1 158052.85 27027.32 182937.34 73016.99 
ABL2/ABL1 388297.30 101083.20 493929.28 153875.20 
ACK1 922657.35 333189.57 745719.99 715348.00 
ACK1 429038.44 144901.52 559607.14 560046.88 
ACTN1 128379.18 136078.11 124709.16 168452.27 
ACTS 617198.57 369574.73 704295.28 656811.68 
ANKL2 1774484.45 2445698.98 1422771.92 2501135.40 
ANXA2 711053.25 281965.01 696757.11 476815.75 
ANXA2 4590724.40 1656585.32 2190044.66 3652219.54 
ANXA2 1218735.63 297124.22 1007833.07 812580.46 
BCAR1 338525.72 170291.96 240378.32 457820.48 
CALR 856490.77 144311.67 1577667.45 352306.49 
CCNL2 98213.39 104840.38 54001.81 114658.33 
CDK1 357808.24 955824.69 624606.45 3886702.79 
CDK2 3574261.61 8766808.98 6128642.02 18815182.68 
CDK3 3396418.72 8328703.27 6794913.38 10262738.33 
CILP2 198869.28 104733.45 157605.84 326180.47 
CML1 110263.22 94791.65 556951.74 470237.14 
879 VINC 512.7556 2 SFLDSGyR 
544 VP13D 428.6271 3 ARDAVSytDK 
1325 ZN483 603.4999 2 AFGysASLTK 
925 ZNF45 383.5233 3 syLQVHLK 
1156 ZO2 639.1482 3 IEIAQKHPDIyAVPIK 
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COF1 86620.46 48305.97 104066.87 95410.82 
CSKI2 721190.38 176123.34 1541311.73 694879.63 
CSKP 218776.87 70649.60 216349.67 74970.31 
DCBD2 425302.85 367333.51 239285.34 215799.23 
DCBD2 401805.37 308981.38 311079.20 620632.76 
DCBD2 142033.39 100294.09 175640.41 262152.16 
DYH6 560410.51 321770.58 265848.97 212790.97 
DYH7 86817.34 62947.91 48393.49 21957.75 
DYR1A 8262429.11 2437101.61 9503113.33 7099249.49 
EF1A1 419470.06 286270.09 506843.26 515893.50 
EGFR 48479.48 31038.18 54539.98 58243.35 
EGFR 153667.34 138807.68 1613495.47 2332661.72 
ENOA 591440.38 263297.31 539507.44 674096.10 
ENOA 813145.43 240266.06 1003193.55 517421.27 
ENOA 163483.09 77074.08 184819.13 137985.92 
ENOG 163908.51 382148.71 440202.16 370887.04 
EVPL 110101.06 17203.91 190048.12 135678.82 
FKBP4 186902.72 449656.21 146856.64 414893.25 
GCYA3 290009.12 419760.09 318321.48 271937.53 
GDE 751602.89 1237566.66 714019.64 1570468.93 
GDE 1086822.68 673636.30 403062.21 832924.82 
GRLF1 551726.17 127120.43 578900.76 131611.28 
GRLF1 3769455.06 735348.48 4058405.24 3251988.54 
GRLF1 647273.97 264677.75 531222.95 453676.11 
GSK3A 292438.80 116195.30 406780.29 308156.27 
GSK3A 1284481.07 361673.58 2258000.97 1052806.79 
GSK3A/GSK3B 58973570.27 18487522.61 68422426.76 51875222.35 
IMPG1 48187.08 18389.24 54606.81 61369.63 
ITB1 414073.39 105515.75 249640.44 253044.23 
ITIH2 213895.65 551833.13 168948.65 1180317.74 
ITSN1 191846.80 254251.42 144069.95 99209.40 
K2C1B 1004608.92 428898.19 819603.07 800675.38 
LDHA 178060.84 356635.60 200782.47 276784.13 
LDHA 937046.05 246653.48 1004697.90 334786.50 
LRCC1 891307.14 1987929.83 510156.21 1177797.79 
LY75 951036.24 704593.96 1688136.87 1091289.86 
M3K8 222848.73 60605.74 196627.13 92722.08 
MK01 6162581.65 3025377.73 8683044.75 4169461.99 
MK01 982491.32 2458393.65 6949922.49 4580568.60 
MK03 4030442.06 2575478.19 5685960.73 4674193.25 
MK03 1556220.89 1093051.82 2897934.66 2900633.59 
MK14 460716.59 147457.89 493933.75 243555.30 
MK14 421256.65 197804.34 595724.34 152649.85 
MLL3 13577863.43 7888312.09 22925084.03 11205540.01 
NP1L2 603266.04 1629862.91 569777.91 1653791.99 
ODPAT 46419.13 50736.35 260792.17 136124.88 
OR8J1 113892.36 96435.46 136819.70 57195.30 
OSBL5 217517.75 1057819.60 556028.01 183019.46 
PAXI 142911.89 74099.51 128332.51 204732.17 
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PAXI 3425913.02 717944.37 2163262.61 2984657.09 
PAXI 1481296.61 385555.40 986958.93 2019925.20 
PAXI 668854.90 170925.79 629594.94 603031.16 
PRP4B 62508210.09 10700694.99 38639222.94 42857360.56 
PRP4B 970333.54 249949.54 542897.06 933738.06 
PRRC1 680073.39 271494.39 690468.92 1118398.09 
PTN11 353620.17 484080.79 355906.63 595519.07 
PTPRA 180804.24 106987.14 78080.90 205051.99 
PTPRA 328479.48 519433.10 363376.01 562648.10 
PTRF 265348.74 301795.53 622019.56 614181.95 
PUR8 471549.51 112110.67 775696.15 208785.66 
RGPD3 268844.55 445067.02 265452.70 446122.77 
RHG42 145980.20 26016.70 214772.27 154456.97 
RIN1 1361034.49 1129682.34 1106079.43 824274.14 
S12A5 68673.86 589706.43 135749.53 132364.21 
SETB2 90142.09 200632.22 123086.89 135194.12 
SHB 479254.88 137621.34 280839.62 169672.56 
SHB 264818.99 149017.29 458824.90 311520.14 
SHC1 119915.23 113395.27 449191.18 925914.91 
SMC1B 166241.83 65420.99 135669.71 180261.30 
SRC8 516368.90 409707.97 503111.45 496457.58 
SSH1 162164.28 199662.87 186439.31 237512.98 
STA13 362436.22 58877.91 717986.29 222776.68 
STAR9 934283.08 389216.91 550970.60 658491.40 
STAT3 529238.13 296316.17 668754.82 302675.77 
SYNE1 701296.76 431172.62 585429.11 505765.76 
TEKT4 155574.86 22708.13 106416.80 49106.18 
TITIN 554417.65 135557.02 110192.85 295694.52 
TITIN 85602.64 118260.96 234272.73 398067.72 
TLN1 411342.53 832645.65 1269804.27 829497.92 
TLN1 473842.88 172340.28 340899.78 260559.94 
TLN1 267913.94 79250.33 248350.52 248087.55 
TLN1 803581.90 206432.88 675670.12 362316.34 
TPP2 133942.55 44955.13 429553.76 169451.57 
TYK2 234589.59 181405.55 363538.63 340488.76 
UBP36 46025.10 426206.40 101046.95 34069.23 
VIME 577122.99 338176.91 845643.65 522585.07 
VIME 737212.49 165750.07 455206.91 318707.84 
VIME 496835.10 360392.85 418098.89 142685.35 
VINC 916028.31 237204.26 751924.80 419799.49 
VP13D 284079.75 64221.07 234289.97 154684.58 
ZN483 329195.30 423184.49 301593.77 537240.64 
ZNF45 2017668.03 1894840.99 2362456.32 2744836.59 
ZO2 594539.30 241264.93 492106.00 246486.65 
 
Table 6. Mean abundance of all tyrosine-phosphorylated peptides that 
were identified by mass spectrometry. Listed are average phosphotyrosine 
intensities that were quantified for each peptide. 
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Since HGF expression decreases with c-Met knockdown, we were 
interested in determining which phosphotyrosine peptides changed the most in 
response to the c-Met signal in U87 and U87 ∆EGFR cells. Therefore, we 
determined which peptides showed the most significant decrease in tyrosine 
phosphorylation with c-Met knockdown in U87 sh-control cells and in U87 sh-
control ∆EGFR cells (Table 7). Those identified to decrease significantly in their 
tyrosine phosphorylation status with c-Met knockdown in U87 sh-control ∆EGFR 
cells, also had significantly reduced phosphotyrosine levels with c-Met silenced in 
U87 sh-control cells. 
 
 
 
 
Table 7. Peptides showing a significant decrease in tyrosine 
phosphorylation with c-Met knockdown. Listed are peptides that showed the most 
significant decrease in intensity of their phosphotyrosine signal with c-Met 
knockdown in U87 sh-control and in U87 sh-control ∆EGFR cells (P < 0.05 was 
considered significant; Student’s t-test; n = 2; duplicate samples per experiment). 
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Mass spectra [intensity versus m/z (mass-to-charge ratio) plot] for all 
phosphotyrosine-modified peptides that were most significantly attenuated in 
response to c-Met knockdown in U87 sh-control and U87 sh-control ∆EGFR cells 
are provided in Figure 28-1 through Figure 28-20. 
 
 
 
Figure 28-1. Mass spectrum of the abl interactor 1 (ABl1) Y198 peptide. 
This spectrum shows Y198 phosphorylation 
[(R)NTPyKTLEPVKPPTVPNDYMTSPAR(L)]. Peptide Index: 1233.  
 
 
 
 
Figure 28-2. Mass spectrum of the abl interactor 1 (ABl1) Y213 peptide. 
This spectrum shows Y213 phosphorylation [(K)TLEPVKPPTVPNDyMTSPAR(L)]. 
Peptide Index: 1157. 
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Figure 28-3. Mass spectrum of the annexin A2 (ANXA2) Y238 peptide. 
This spectrum shows Y238 phosphorylation [(K)SYSPyDMLESIR(K)] . Peptide 
Index: 1653.  
 
 
 
 
Figure 28-4. Mass spectrum of the mitogen-activated protein kinase 14 
(MK14) (MAPK14) Y182 peptide. This spectrum shows Y182 phosphorylation 
[(R)HTDDEMTGyVATR(W)]. Peptide Index: 719. 
 
 
 
 
Figure 28-5. Mass spectrum of the L-lactate dehydrogenase A (LDHA) 
Y247 S249 peptide. This spectrum shows Y247 and S249 phosphorylation 
[(K)GyTsWAIGLSVADLAESIMKNLR(R)]. Peptide Index: 2247.  
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Figure 28-6. Mass spectrum of the glycogen synthase kinase 3 α/β 
(GSK3A/B) Y279 S282 peptide. This spectrum shows Y279 and S282 
phosphorylation [(R)GEPNVSyICsR(Y)]. Peptide Index: 808.  
 
 
 
 
Figure 28-7. Mass spectrum of the enolase A (ENOA) (ENO1) Y44 
peptide. This spectrum shows Y44 phosphorylation 
[(R)AAVPSGASTGIyEALELR(D)]. Peptide Index: 1608. 
 
 
 
 
Figure 28-8. Mass spectrum of the glycogen synthase kinase 3α/β 
(GSK3A/B) Y279 peptide. This spectrum shows Y279 phosphorylation 
[(R)GEPNVSyICSR(Y)]. Peptide Index: 841. 
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Figure 28-9. Mass spectrum of the src homology 2 domain-containing 
adapter protein B (SHB) Y268 peptide. This spectrum shows Y268 
phosphorylation [(K)GESAGyMEPYEAQR(I)]. Peptide Index: 801. 
 
 
 
 
Figure 28-10. Mass spectrum of the serine/threonine-protein kinase PRP4 
homolog (PRP4B) Y849 peptide. This spectrum shows Y849 phosphorylation 
[(K)LCDFGSASHVADNDITPyLVSR(F)]. Peptide Index: 1410. 
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Figure 28-11. Mass spectrum of the StAR-related lipid transfer protein 13 
(STA13) (STARD13) Y39 peptide. This spectrum and table provides data that 
indicates Y39 phosphorylation [(R)FDQTTRRSPyR(M)]. Peptide Index: 895. 
 
 
 
 
Figure 28-12. Mass spectrum of the Rho-GTPase-activating protein 42 
(RHG42) Y792 peptide. This spectrum shows Y792 phosphorylation 
[(R)LDTASSNGyQRPGSVVAAK(A)]. Peptide Index: 741. 
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Figure 28-13. Mass spectrum of the paxillin (PAXI) (PXN) Y88 peptide. 
This spectrum shows Y88 phosphorylation [(R)FIHQQPQSSSPVyGSSAK(T)]. 
Peptide Index: 736. 
 
 
 
  
Figure 28-14. Mass spectrum of the glucocorticoid receptor DNA binding 
factor 1 (GRLF1) Y1105 peptide. This spectrum shows Y1105 phosphorylation 
[(R)NEEENIySVPHDSTQGK(I). Peptide Index: 770]. 
 
 
 
 
 
Figure 28-15. Mass spectrum of activated CDC42 kinase (ACK1) (TNK2) 
Y518 peptide. This spectrum shows Y518 phosphorylation 
[(K)KPTyDPVSEDQDPLSSDFKR(L)]. Peptide Index: 1063. 
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Figure 28-16. Mass spectrum of the mitogen-activated protein kinase 1 
(MK01) (MAPK1) Y185 peptide. This spectrum shows Y185 phosphorylation 
[(R)VADPDHDHTGFLTEyVATR(W)]. Peptide Index: 1083. 
 
 
 
  
Figure 28-17. Mass spectrum of the vinculin (VINC) Y822 peptide. This 
spectrum shows Y822 phosphorylation [(K)SFLDSGyR(I)]. Peptide Index: 879. 
 
 
 
           
Figure 28-18. Mass spectrum of the glucocorticoid receptor DNA-binding 
factor 1 (GRLF1) Y1087 peptide. This spectrum shows Y1087 phosphorylation 
[(K)SVSSSPWLPQDGFDPSDyAEPMDAVVKPR(N)]. Peptide Index: 1890. 
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Figure 28-19. Mass spectrum of the vimentin (VIME) (VIM) Y61 peptide. 
This spectrum shows Y61 phosphorylation [(R)SLYASSPGGVyATR(S)]. Peptide 
Index: 906. 
 
 
 
Figure 28-20. Mass spectrum of the Vimentin (VIME) (VIM) Y150 peptide. 
This spectrum and table provides information that shows Y150 phosphorylation 
[(R)LGDLyEEEMR(E)]. Peptide Index: 947. 
 
 
We used Ingenuity Pathway Analysis (IPA; http://www.ingenuity.com) to 
determine which c-Met-dependent signaling pathways are responsible for 
decreased HGF expression. To do this, we used IPA software to connect known 
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modulators of HGF expression (Ingenuity Knowledge Base) with all of the 
peptides that were identified in Table 7 to decrease significantly with c-Met 
knockdown in U87 sh-control and U87 sh-control ∆EGFR cells (Figure 29). Ten 
out of the possible sixteen proteins that were listed in Table 7 formed biological 
relationships with proteins found within Ingenuity Knowledge Base’s database that 
would lead to HGF expression. The majority of the proposed signaling pathways 
converged on STAT3. Therefore, our data suggested that STAT3 signaling may 
play a key role in regulating HGF expression in a c-Met-dependent manner.  
 
 
 
Figure 29. Ingenuity pathway analysis of c-Met-dependent 
phosphopeptides identified by mass spectrometry that may modulate HGF 
expression. Biological relationships that lead to HGF expression were explored in 
Ingenuity Knowledge Base’s database from peptides that were identified by 
PhosphoScan analysis as being responsive to the c-Met signal in U87 cells (Dr. 
Vaibhav Chumbalkar, Dr. Oliver Bögler’s former post-doctoral fellow, assisted with 
IPA analysis). 
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Although STAT3 did not surface in our mass spectrometry-based screen as 
a significantly changed phosphopeptide with c-Met knockdown, it was identified in 
all of the cell lines that were processed for mass spectrometry analysis (Figure 
30), and confirmed to decrease with c-Met knockdown in U87 and U87 ∆EGFR 
cells (Figure 31A). This finding was confirmed in cell lysates from the cell lines 
that were processed for Phosphoscan analysis (Figure 31B). 
 
 
  
 
Figure 30. Mass spectrum of the signal transducer and activator of 
transcription 3 (STAT3) Y705 peptide. This spectrum shows Y705 phosphorylation 
[(K)YCRPESQEHPEADPGSAAPyLK(T)]. Peptide Index: 2345. 
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Figure 31. STAT3 Y705 phosphorylation decreases with c-Met knockdown 
in U87 and U87 ∆EGFR cells. (A) PhosphoScan mean intensity values (105) of 
STAT3 Y705 phosphorylation in U87 sh-control cells with or without c-Met 
knockdown and / or ∆EGFR expression (n = 2; duplicate samples per experiment; 
mean abundance ± SEM). (B) Western blot validation of pSTAT3 Y705 
phosphorylation in cells that were analyzed by mass spectrometry.  
 
 
Inhibition of the c-Met and ∆EGFR signal in U87 ∆EGFR cells with AG1478 
and SU11274 treatment, respectively, effectively decreased the phosphorylation 
of STAT3 (Y705) and of Src (Y416) (Figure 32), a known non-receptor tyrosine 
kinase that activates STAT3 by phosphorylation at Y705 (Wojcik et al., 2006).  
Even though Src (Y416) phosphorylation was attenuated with EGFR and c-Met 
inhibition in U87 parental cells, STAT3 (Y705) phosphorylation was not as strongly 
attenuated. We also observed that STAT3 (Y705) phosphorylation did not 
increase in intensity with ∆EGFR expression in U87 cells, consistent with findings 
in previous reports (Huang et al., 2009). 
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Figure 32. STAT3 activity decreases with c-Met and ∆EGFR inhibition in 
U87 ∆EGFR cells. Western blot analysis of U87 and U87 ∆EGFR cells that were 
treated for 20 h with either 0.1% DMSO, 10 μM AG1478 (EGFR and ∆EGFR 
antagonist), 10μM SU11274 (c-Met antagonist), a combination of 10 μM AG1478 
and 10μM SU11274, 10 μM PP2 (Src antagonist), 2.5 μM WP1193 (STAT3 
antagonist), or a combination of 10 μM PP2 and 2.5 μM WP1193. Src and STAT3 
inhibition with PP2 and WP1193, respectively, served as positive controls. Cells 
were cultured in 10% FBS-containing media. 
 
 
Taken together, these data suggest that the phosphorylation of STAT3 at 
Y705 is modulated by c-Met in U87 cells, and that STAT3 may be an important 
signaling effector necessary for HGF production in these cells.  
 
 
STAT3 Partially Rescues Attenuated HGF and Anchorage-
independent Growth of c-Met Silenced U87 ∆EGFR Cells 
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Given that STAT3 most likely regulates HGF expression in response to the 
c-Met signal in GBM cells, we tested if inhibition of STAT3 activity could modulate 
HGF expression. We treated U87 ∆EGFR cells with WP1193, a phosphorylation 
inhibitor of STAT3 Y705 (Kong et al., 2010), and analyzed HGF mRNA expression 
by qRT-PCR in these cells. We found that with STAT3 Y705 inhibition that HGF 
mRNA levels were attenuated (Figure 33A). The inhibition of STAT3 Y705 
phosphorylation following the treatment of U87 ∆EGFR cells with WP1193 was 
confirmed by western blot (Figure 33B). 
 
 
 
Figure 33. STAT3 Y705 inhibition attenuates HGF mRNA expression in 
U87 ∆EGFR cells. (A) HGF mRNA amounts were quantified in U87 ∆EGFR cells 
by qRT-PCR after 16 h of being untreated (-), or after they were treated with 
vehicle (0.1% DMSO) or with 2.5 μM WP1193 (STAT3 phosphorylation inhibitor). 
Cells were cultured in media containing 10% FBS (* = P < 0.05; Student’s t-test 
compared with DMSO-treated cells; n = 3±SEM; samples were analyzed at least 
in duplicate per experiment). (B) Aliquots of the cells that were treated in (A) were 
analyzed using western blotting techniques to ensure that WP1193 had 
decreased STAT3 Y705 phosphorylation.  
 
 
 
98 
 
Constitutively activate STAT3, produced by substitution of two SH2 
domain cysteine residues with Ala661 and Asn664 (Bromberg et al., 1999; Ning et 
al., 2001), spontaneously dimerizes to enhance STAT3’s function as a 
transcription factor (Bromberg et al., 1999). We tested whether the expression of 
constitutively active STAT3 (STAT3-CA) would be able to rescue the HGF 
production deficit found in U87 sh-control ∆EGFR cells with c-Met knockdown. We 
overexpressed an empty vector control or STAT3-CA in U87 sh-control ∆EGFR 
and in U87 sh-c-Met #B2 ∆EGFR cells, and analyzed their HGF mRNA 
abundance by q-RT-PCR and by western blot. We found that STAT3-CA partially 
rescued HGF mRNA (Figure 34A) and protein (Figure 34B) amounts in ∆EGFR-
expressing GBM cells with c-Met knockdown. 
 
 
Figure 34. Constitutively active STAT3 partially rescues HGF expression in 
c-Met silenced U87 ∆EGFR cells. (A) qRT-PCR quantified HGF mRNA amounts in 
U87 sh-control ∆EGFR pcDNA3.1-E cells, U87 sh-control ∆EGFR STAT3-CA 
cells, U87 sh-c-Met #B2 ∆EGFR pcDNA3.1-E cells, and in U87 sh-c-Met #B2 
∆EGFR STAT3-CA cells. Cells were cultured in media containing 10% FBS 
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(P<0.01; Student’s t-test; n = 3±SEM; samples were analyzed at least in duplicate 
per experiment). (B) All cells detailed in (A) were analyzed for their HGF 
expression and STAT3 Y705 phosphorylation by western blot. 
 
 
In an effort to determine whether the promoter activity of HGF, which 
contains a STAT3 consensus binding site in the proximal promoter at -99/-91 
(TTACCGTAA; Tomida and Saito, 2004), would decrease with c-Met knockdown 
in U87 cells we performed promoter assays. We initially examined if the activity of 
a HGF-1029-luciferase reporter (Figure 35A) would increase compared with a 
pGL2-basic construct in U87 cells. By doing this, we determined that the HGF-
1029-luciferase construct was functional (Figure 35B). Surprisingly, we found that 
HGF promoter activity with the first -1029 bp did not decrease with silencing of c-
Met in U87 cells (Figure 35C). These data suggested that the HGF gene may be 
regulated transcriptionally beyond the first -1029 base pairs, or that HGF 
expression may be modulated at the RNA level. 
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Figure 35. HGF promoter activity is unresponsive to c-Met knockdown in 
U87 cells. (A) Schematic of the pGL2-HGF-luciferase (-1029 bp) reporter 
construct used to examine HGF promoter activity in (B) and (C). The STAT3 
consensus binding site at circa -100 bp is depicted. (B) U87 cells were transfected 
with a HGF-1029-luciferase reporter construct or a pGL2-basic-luciferase reporter 
construct along with a pSV-β-galactosidase construct and then harvested for 
measurement of luciferase and β-galactosidase activity (± SEM). (C). Luciferase 
assays measured the activity of the HGF-1029 promoter construct when 
transfected into U87, U87 sh-control, U87 sh-c-Met #A2 and U87 sh-c-Met #B2 
cells (normalized to β-galactosidase activity; n=2 ± SEM). 
 
 
To determine if the stability of HGF mRNA was affected with c-Met 
knockdown in U87 cells, we pretreated U87, U87 sh-control, U87 sh-c-Met #A2, 
and U87 sh-c-Met #B2 cells with actinomycin D, a transcription inhibitor, for 1 h 
and then quantified HGF mRNA levels at 0 h and 8 h by qRT-PCR. HGF did not 
decay at a faster rate in U87 cells with c-Met knockdown than in U87 parental or 
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U87 sh-control cells within 8 h (Figure 36). c-Myc was used as a positive control, 
due to its rapid turnover rate in U87 cells (Marderosian et al., 2006). These results 
fail to show a profound impact on HGF mRNA stability, and so indicate that c-Met-
dependent HGF regulation was most likely not due to post-transcriptional 
instability of mRNA.  
 
 
 
Figure 36. c-Met knockdown does not affect HGF mRNA stability. Q-RT-
PCR measured HGF mRNA amounts at 0 h and 8 h following the exposure of U87 
cells to 5 ug / mL Actinomycin D (samples were analyzed in triplicate and 
compared relative to cells analyzed at t0; c-myc mRNA instability served as a 
positive control). 
 
 
 
We determined if STAT3-CA could restore the loss in anchorage-
independent growth that we had observed with c-Met knockdown in U87 ∆EGFR 
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cells (Figure 23). By performing in vitro colony formation assays, we found that 
STAT3-CA was capable of partially restoring deficits in anchorage-independent 
growth found with c-Met knockdown in these cells (Figure 37). This effect was 
comparable to its capability of rescuing HGF expression in c-Met knockdown cells 
(Figure 34). 
 
 
 
 
Figure 37. STAT3 partially rescues colony formation associated with c-Met 
knockdown in U87 ∆EGFR cells. Anchorage-independent growth was assessed 
using U87 sh-control ∆EGFR pcDNA3.1-E cells, U87 sh-control ∆EGFR STAT3-
CA cells, U87 sh-c-Met #B2 ∆EGFR pcDNA3.1-E cells, and U87 sh-c-Met #B2 
∆EGFR STAT3-CA cells after 14 days in culture (* = P<0.05; Student's t-test; n = 
3 ± SEM; samples were analyzed at least in duplicate per experiment). 
 
 
Our results therefore suggest that STAT3 is a key signaling effector that 
regulates HGF expression in response to c-Met signaling in ∆EGFR-expressing 
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GBM cells, although it does not appear to be the only regulator. Other pathways 
are therefore most likely required for maximal HGF expression in this model 
(Figure 38). Taken together, our data suggest that the ligand-dependent and 
ligand-independent activation of c-Met drives HGF expression partly via STAT3. 
 
 
 
 
Figure 38. Proposed model of enhanced HGF expression via c-Met 
activation in GBM cells. 
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CHAPTER 6 
  
RESULTS 
 
THE C-MET / HGF AXIS IS UPREGULATED IN 
MESENCHYMAL GBM TUMORS 
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Using IPA, we showed that STAT3 activity is necessary, but still requires 
additional signaling pathways, for HGF expression in response to the c-Met signal 
in GBM cells (Figure 29); a finding subsequently validated in vitro (Figure 34). The 
IPA bioinformatic analysis identified that C/EBPβ and STAT3 are dependent on 
the same upstream signaling effectors that are required for c-Met-dependent HGF 
expression, suggesting that they may work in concert to maximally upregulate 
HGF expression.  
STAT3 and C/EBPβ are master regulators of the mesenchymal GBM 
subtype (Carro et al., 2010). This subclass of GBM tumors is associated with a 
poorer prognosis compared with proneural tumors (Phillips et al., 2006). YKL-40, 
a mesenchymal signature gene, confers resistance to radiotherapy (Pelloski et al., 
2005) and is upregulated in recurrent tumors (Phillips et al., 2006). This was 
consistent with an observation that many recurrent tumors tend to shift their gene 
expression signature to that of the mesenchymal GBM subtype (Phillips et al. 
2006). Based on our prior bioinformatic data that processed c-Met dependent 
phosphopeptides in the context of HGF regulation, we were interested in 
determining whether the c-Met / HGF axis is upregulated in mesenchymal GBM 
tumors. TCGA GBM tumors have been classified into four subtypes by Verhaak 
and colleagues (2010) based on specific signature gene sets for each GBM 
subtype; with those subtypes being mesenchymal, proneural, neural, and 
classical. We extracted c-Met and HGF gene expression values (Agilent platform; 
TCGA’s GBM level 3 gene expression data) for each tumor that had already been 
classified as one of the four GBM subclasses by Verhaak et al., 2010. Elevated c-
Met (Figure 39) and HGF (Figure 40) mRNA expression associated significantly 
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with the mesenchymal GBM subtype when compared with tumors having a 
proneural, neural, or classical assignment. 
 
 
 
 
Figure 39. c-Met mRNA expression is upregulated in the mesenchymal 
GBM subtype (Verhaak determined). c-Met mRNA abundance was determined in 
tumors that were assigned as one of four GBM subtypes (mesenchymal, 
proneural, neural, and classical) by Verhaak and colleagues (2010). Level 3 
mRNA expression data was downloaded from TCGA, which was represented as a 
Log10 ratio to a reference RNA (* = P<0.05; *** = P<0.001; Welsh’s t-test 
compared with the mesenchymal GBM subtype; n= 200; Dr. Brian Vaillant, Dr. 
Howard Colman’s former post-doctoral fellow, performed this analysis). 
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Figure 40. Enhanced HGF mRNA expression associates with the 
mesenchymal GBM subtype (Verhaak determined). HGF mRNA expression was 
determined in tumors that were assigned a GBM subtype (mesenchymal, 
proneural, neural, and classical; Verhaak et al., 2010). TCGA levels 3 mRNA 
expression data were represented as a Log10 ratio to a reference RNA (*** = 
P<0.001; Welsh’s t-test compared with the mesenchymal GBM subtype; n = 200; 
Dr. Brian Vaillant, Dr. Howard Colman’s former post-doctoral fellow, performed 
this analysis). 
 
 
 
At the time when Verhaak and colleagues (2010) classified TCGA GBM 
tumors into either mesenchymal, proneural, neural, or classical subtypes, there 
were only 200 GBM tumors in the database with gene expression profiles. Since 
then, the TCGA database has included gene expression data for an additional 
295 tumors. Therefore, we wanted to examine whether our initial findings, which 
showed that enhanced c-Met and HGF expression correlated with mesenchymal 
GBM tumors, would remain robust in an analysis that made use of a larger 495 
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tumor dataset. Verhaak and colleagues (2010) defined specific lists of gene sets 
for the various GBM subtypes, which we used to calculate average metagene 
expression values for each tumor. Tumors were then assigned to a GBM subtype 
based on the highest average metagene score. We then analyzed each tumor for 
their c-Met and HGF mRNA expression. In agreement with our previous data, we 
found that their higher expression levels correlated with the mesenchymal GBM 
subtype (Figure 41 and Figure 42, respectively). 
 
 
 
 
Figure 41. c-Met mRNA expression is elevated in mesenchymal GBM 
tumors (Verhaak calculated). Tumors were assigned a GBM classifier 
(mesenchymal, proneural, neural, classical) according to the highest metagene 
score for each GBM subtype, from lists previously defined by Verhaak et al. 
(2010). c-Met mRNA expression (log10 ratios to reference RNA) levels were then 
documented per tumor (*** = P<0.001; Welsh’s t-test compared with the 
mesenchymal GBM subtype; n = 495; Dr. Brian Vaillant, Dr. Howard Colman’s 
former post-doctoral fellow, performed this analysis). 
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Figure 42. Mesenchymal GBM tumors express increased levels of HGF 
mRNA (Verhaak calculated). GBM tumors (495) were designated as 
mesenchymal, proneural, neural or classical as defined by gene lists reported by 
Verhaak et al., 2010. TCGA HGF mRNA expression, expressed as log10 ratios to 
a reference RNA, were then documented per tumor (*** = P<0.001; Welsh’s t-test 
compared with the mesenchymal GBM subtype; n = 495; Dr. Brian Vaillant, Dr. 
Howard Colman’s former post-doctoral fellow, performed this analysis). 
 
 
 
Phillips and colleagues (2006) were the first authors to describe a set of 
genes that classified mesenchymal, proneural, and proliferative GBM tumors. 
They clearly showed that patient survival was significantly impacted if GBMs were 
either mesenchymal or proliferative, compared with those patients having 
proneural tumors; mesenchymal tumors had the worst prognosis. Both Phillips et 
al., 2006 and Verhaak et al., 2010 identified the mesenchymal and proneural GBM 
subclasses, assigning them with similar functional definitions, however their gene 
lists for each of these subtypes differed. We used the gene lists described by 
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Phillips et al., 2006 for mesenchymal, proneural, or proliferative GBM tumors in 
the TCGA dataset to determine which subclass had the highest c-Met and HGF 
expression. We found that increased levels of c-Met and HGF mRNA expression 
associated most with the mesenchymal class of GBM tumors that were defined by 
Phillips et al. (2006), although there was no significant difference in expression 
between the mesenchymal and proliferative GBM subclasses (Figure 43 and 
Figure 44, respectively). Significantly, the proneural GBMs expressed much less 
c-Met and HGF than mesenchymal tumors, suggesting that survival may be 
impacted with greater abundance of the c-Met / HGF axis, which is consistent with 
a previous report (Kong et al., 2009). 
 
 
Figure 43. Mesenchymal and 
proliferative GBM tumors express elevated c-
Met mRNA levels (Phillips calculated). c-Met 
mRNA expression (log10 ratios to reference 
RNA) for 495 GBM tumors was downloaded 
from the TCGA database. Each GBM tumor 
was subclassified as a GBM subtype 
(mesenchymal, proliferative, or proneural). 
This was based on the highest average gene 
list score per GBM subtype, as defined by 
Phillips et al., 2006 (*** = P<0.001; Welsh’s t-
test compared with the mesenchymal GBM 
subtype; n = 495; P<0.01 when c-Met 
expression was compared in proliferative 
versus proneural GBMs using Welsh’s t-test; 
Dr. Brian Vaillant, Dr. Howard Colman’s 
former post-doctoral fellow, performed this 
analysis). 
 
 
 
 
111 
 
 
 
Figure 44. Increased HGF mRNA expression associates most with the 
mesenchymal and proliferative GBM subtypes (Phillips calculated). HGF gene 
expression values were extracted from the TCGA database for 495 GBM tumors. 
Each tumor was assigned to either the mesenchymal, proliferative, or proneural 
GBM subtype, according to the highest average metagene score. Gene lists per 
GBM subtype were described by Phillips et al., 2006 (*** = P<0.001; Welsh’s t-test 
compared with the mesenchymal GBM subtype; n = 495; P<0.05 when HGF 
expression was compared in proliferative versus proneural GBMs using Welsh’s t-
test; Dr. Brian Vaillant, Dr. Howard Colman’s former post-doctoral fellow, 
performed this analysis). 
 
 
False-discovery rates in microarray studies are high if only single datasets 
are evaluated; data interpretation would need to be performed with caution 
(Colman et al., 2010). Therefore, we validated our findings in an independent 
sample set of GBM tumors, available in the REMBRANDT database, that were 
processed on a different platform (Affymetrix gene expression platform) to that of 
our previous dataset (Agilent gene expression platform). Average metagene 
scores were calculated per GBM subtype for each tumor, which was based on 
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Verhaak et al., 2010- determined gene lists for the four GBM subtypes. Then, 
tumors were binned to a GBM subtype, and their c-Met and HGF expression 
levels extracted. We found higher c-Met (Figure 45) and HGF (Figure 46) 
expression levels in the mesenchymal-angiogenic GBM subclass compared with 
all others. Proneural and neural tumors did not differ significantly from 
mesenchymal tumors in terms of their overall c-Met expression, which was 
possibly due to the presence of a few outliers in those GBM subtypes and an 
inferior c-Met probe set on the Affymetrix gene expression platform. 
 
 
 
Figure 45. Validation that higher c-Met expression levels associates with 
the mesenchymal GBM subtype in an independent sample set (Verhaak 
calculated). Expression data for GBM tumors were obtained from the 
REMBRANDT database, which were represented as log2 transformed data after 
they had been normalized to pooled normal brain. Tumors were assigned to a 
GBM subtype according to their highest average metagene value per Verhaak 
determined GBM subtype. Gene lists per GBM subtype were described by 
Verhaak et al., 2010 (*** = P<0.001; Welsh’s t-test compared with the 
mesenchymal GBM subtype; n = 180; Dr. Brian Vaillant, Dr. Howard Colman’s 
former post-doctoral fellow, performed this analysis). 
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Figure 46. Independent dataset validation that elevated HGF expression 
levels associate with the mesenchymal GBM subtype (Verhaak calculated). 
mRNA expression data for 180 GBM tumors was obtained from the REMBRANDT 
database. These data were normalized to pooled normal brain expression data, 
and then log2 transformed. Verhaak et al., 2010 determined which genes defined 
each GBM subtype, and accordingly this list was used to calculate an average 
expression score per tumor. Tumors were assigned to a GBM subtype based on 
the highest average expression score, and their HGF expression levels reported 
(*** = P<0.001; Welsh’s t-test compared with the mesenchymal GBM subtype; n = 
180; Dr. Brian Vaillant, Dr. Howard Colman’s former post-doctoral fellow, 
performed this analysis). 
 
 
In summary, our results suggest that upregulation of the c-Met / HGF axis 
is strongly associated with the mesenchymal GBM subtype. Since antagonists of 
this receptor ligand pair are available, our data may be developed further by 
performing additional basic and pre-clinical studies with an eventual goal of being 
able to treat patients according to the molecular subtype of their tumor. 
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CHAPTER 7 
  
DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
115 
 
GBM is a relentless and cruel disease. Not only is it invariably lethal, but 
patients suffer loss of higher neurocognition within a very short amount of time 
(Bosma et al., 2007). Conventional therapies have only slightly improved upon 
patient prognosis over the past few decades, making the expedited identification 
of effective targets necessary (Lassman and Holland, 2007). For these reasons, 
GBM has often been given priority status. For example, GBM was the first cancer 
genome analyzed by the TCGA for important genetic changes that lead to 
dysregulated signaling pathways, even though it is not a very prevalent cancer 
(The Cancer Genome Atlas Research Network, 2008). One such pathway is the c-
Met / HGF signaling axis, which has been found to be a key determinant of brain 
tumor malignancy (Abounader and Laterra, 2009). In studies with a limited 
number of samples, it has been shown that c-Met and HGF coexpression 
increases with glioma grade (Koochekpour et al., 1997; Moriyama et al., 1998). 
We showed for the first time that c-Met and HGF expression are positively 
correlated in a large dataset of 495 GBMs. Importantly, our data revealed that the 
highest expression levels of HGF and c-Met were found in mesenchymal GBM 
tumors; the most aggressive GBM subtype that is associated with the worst 
prognosis (Phillips et al., 2005). Interestingly, HGF appeared to have a stronger 
differentiation for the mesenchymal GBM subgroup than c-Met. This may be due 
to an inferior c-Met probe set, which will not correctly reflect the underlying 
biology. Undeniably however, c-Met and HGF expression are upregulated in 
mesenchymal GBMs compared with proneural, or less aggressive, GBMs. 
Theoretically it would be ideal to have a unified gene set for the mesenchymal 
GBM subtype, however this is limited and complicated by the fact that there are 
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various gene expression platforms containing different gene-specific probe sets, 
and by the statistical tests that were employed to analyze the data. Phillips et al. 
(2006) and Verhaak et al. (2010) identified different gene sets that defined the 
mesenchymal and proneural GBM subtypes. In agreement however, they found a 
subset of GBMs with an aggressive mesenchymal-angiogenic molecular profile, 
which they termed mesenchymal GBMs, and a list of genes known to modulate 
normal neural development, which they named the proneural GBM subtype. Both 
authors’ mesenchymal gene list included YKL-40, a mesenchymal marker protein 
(Carro et al., 2010) associated with a poor outcome for GBM patients (Colman et 
al., 2010; Pellowski et al., 2005). Recurrent GBMs, whether proneural or 
proliferative, tend to shift their molecular profile to that of a mesenchymal 
signature (Phillips et al., 2005). These data suggest that the c-Met / HGF signaling 
axis might be a good target for the treatment of primary mesenchymal GBMs, and 
for recurring GBMs.  With additional preclinical studies into the applicability of 
these findings, we may be a step closer to adding another element of 
personalized patient care for individuals with GBM.  
The mesenchymal or aggressive behavior of GBM usually includes local 
invasion and neo-angiogenesis, which are phenotypic hallmarks of glioma 
malignancy (Carro et al., 2010). Interestingly, we found that the gross morphology 
of U87 cells changed from a mesenchymal-like to an epithelial-like shape 
following knockdown of c-Met, and also with the expression of kinase-deficient c-
Met mutants. These data indicate that the expression and activity of c-Met may be 
important components necessary for preservation of the mesenchymal-like 
appearance, and possibly even mesenchymal behavior, of GBM cells.  
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Another important novel finding of our study is that c-Met signaling 
regulates the expression of HGF in GBM cells. In a complementary study, 
Abounader and colleagues (2001) showed that c-Met expression is 
transcriptionally induced by HGF-mediated c-Met activation in GBM cells. 
Together these findings emphasize the importance of the autocrine c-Met / HGF 
signaling axis in GBM.  Perpetuation of an autocrine signal has also been found in 
many other ligand-receptor systems, including EGFR signaling, as EGFR auto-
induces its own expression in various cancer cell lines (Clark et al., 1985; 
McCulloch et al., 1998; Seth et al., 1999), and of its ligands, HB-EGF, epiregulin, 
and amphiregulin (Chu et al., 2005). Our finding that c-Met signaling modulates 
the expression of its own ligand in GBM cells, suggests that c-Met-dependent 
biological programs, such as cellular proliferation, mobility, invasion, 
angiogenesis, and tumorigenicity (Abounader and Laterra, 2009) may be amplified 
in GBM as a consequence of this regulation. 
That these interconnections at the level of signaling and expression are 
relevant to the biology of the disease is supported by our findings in culture and 
animal models. We found that c-Met expression was necessary for U87 cells to 
form colonies in three-dimensional cultures, and to maintain the tumorigenic 
potential of orthotopic U87 xenografts. HGF expression was attenuated with c-Met 
knockdown in vitro to the same extent that tumorigenicity decreased in vivo. It is 
therefore possible that the two findings are mechanistically connected, and that 
regulation of the c-Met / HGF autocrine signal plays a key role in the 
tumorigenicity of c-Met-dependent U87 cells. In agreement with what we found, 
others have shown that the tumorigenicity of intracranial U87 xenografts was 
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attenuated with c-Met (Martens et al., 2006) or HGF (Pillay et al., 2009) 
antagonism. That this pathway may not be present in all GBM cells is suggested 
by the work of Martens and colleagues (2006), who showed that a non-c-Met-
dependent GBM cell line, meaning that it did not coexpress c-Met and HGF 
(Beroukhim et al., 2007), did not respond to anti-c-Met therapy in vivo. This finding 
was further explored in vitro by Beroukhim and colleagues (2007). They provided 
data to suggest that enhanced cytotoxicity could only be achieved with a c-Met 
TKI in GBM cells that coexpressed c-Met and HGF. Strikingly, when Lal and 
colleagues (2005) cotargeted c-Met and HGF with U1/ribozymes in preestablished 
intracranial U87 xenografts, and then subjected the mice to hypofractionated γ-
radiation, 80% of the mice survived long-term. The efficacy of non-targeted 
standard chemotherapeutic agents similarly enhanced the survival of mice when 
used in conjunction with an anti-HGF neutralizing antibody in U87 cells and 
xenografts (Jun et al., 2007). Taken together, these data suggest that targeting 
the c-Met signaling axis in GBMs that are dependent upon the autocrine HGF 
signal for their anchorage-independent growth and tumorigenicity, either before or 
after standard care treatment regimens, may be a powerful strategy for therapy of 
these tumors. However, we would also like to point out the limitation that not all 
GBMs, or even all cells in any one GBM, are likely to be susceptible to this 
approach, and that careful analysis of the expression of both c-Met and HGF 
needs to precede application of such therapies.  
In cancer cell lines, such as thyroid carcinoma, GBM (Reznik et al., 2008), 
NSCLC (Xu et al., 2010), bladder carcinoma (Yamamoto et al., 2006), and breast 
carcinoma (Bonine-Summers et al., 2007; Mueller et al., 2010), a significant 
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amount of pathway crosstalk occurs between the EGFR and c-Met signaling axes. 
Not only does the EGFR transactivate the c-Met receptor in various cancer cell 
lines (Bergström et al., 2000; Fischer et al., 2004), but c-Met signaling also 
modulates the activity of the EGFR in c-Met-dependent gastric cancer cells 
(Bachleitner-Hofmann et al., 2008). Oncogene switching also takes place between 
c-Met and EGFR, where alternate receptor activation is a mechanism employed 
by cancer cells to compensate for loss of function of the other receptor (Mueller et 
al., 2008; Bachleitner-Hofmann et al., 2008). As a result, the activity of c-Met has 
been reported to be a key factor circumventing the effectiveness of EGFR TKIs 
(Tang et al., 2008). Therefore, greater therapeutic efficacies have been 
accomplished by cotargeting c-Met and EGFR in tumors that have become 
resistant to EGFR TKIs (Tang et al., 2008). Our laboratory has shown that Y1235 
of c-Met is activated by EGF-stimulated EGFR in GBM cells (Chumbalkar et al., 
2011), which suggests that crosstalk between c-Met and EGFR may play an 
important role in GBM, which may ultimately be targetable. 
We have shown that many GBMs contain a robust HGF autocrine loop that 
is inducible through c-Met signaling, and Abounader et al. (2001) provided 
evidence that HGF-mediated c-Met activation induces the expression of the c-Met 
gene. As a result of enhanced HGF expression, dysregulated HGF / c-Met 
signaling most likely leads to c-Met overexpression. Once overexpressed, 
receptors may be activated in a ligand-independent manner due to their closer 
proximity with other RTKs (Mineo et al., 1999). This occurs especially when a 
receptor is a preferential target of those nearby receptors, such as is the case with 
c-Met activation being a preferred downstream signaling pathway for the ∆EGFR 
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(Chumbalkar et al., 2011; Huang et al., 2007; Pillay et al., 2009). It is still unclear 
whether ∆EGFR transactivates c-Met directly, or whether intermediary signaling 
effectors are necessary for ∆EGFR-mediated c-Met activation in GBM cells, but 
we do know that they associate in a complex (data not shown). We showed that c-
Met activation by ∆-EGFR enhances HGF expression, which provides a rationale 
for targeting HGF in GBMs that express the ∆EGFR. However, Pillay et al. (2009) 
showed that HGF antagonism of U87 ∆EGFR-expressing intracranial xenografts 
was ineffective. This was contrary to what they found when they treated U87 cells, 
and U87 cells that expressed the WT EGFR, with the same anti-HGF monoclonal 
antibody. We propose that HGF neutralizing antibody treatment of GBMs 
expressing ΔEGFR may not reach therapeutic efficacy levels, due to incomplete 
neutralization of the higher amounts of HGF that are most likely being produced in 
these tumors. This idea is supported by a remarkable reduction in tumorigenicity 
when ∆EGFR-driven GBM xenografts are treated with anti-HGF and anti-EGFR 
therapies in combination, compared with either agent alone (Lal et al., 2009; Pillay 
et al., 2009). 
Depending on the cellular context, the c-Met / HGF signaling axis can 
promote either survival or apoptosis (Trusolino et al., 2010). Interestingly, HGF 
has been called ‘tumor cytotoxic factor’, because excessive amounts of this 
cytokine may induce apoptosis in various cancer cell lines (Trusolino et al., 2010). 
It has been suggested that higher levels of HGF may titre out the available ligand-
binding domains of c-Met on the cell surface, thereby liberating bound FAS, a 
death receptor that often associates with c-Met as a survival mechanism, and 
hence promote apoptosis (Trusolino et al., 2010). However, we and others have 
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shown that ∆EGFR-expressing GBM cells express high levels of BCL-XL (Nagane 
et al., 1996), which may likely serve to promote cell survival while still maintaining 
constitutive ligand-dependent and ligand-independent c-Met activity. 
We found that c-Met was required by ∆EGFR to maintain its elevated 
production of HGF in U87 cells. We also showed that when c-Met’s expression 
was silenced in U87 cells expressing ∆EGFR, the tumorigenicity of intracranial 
xenografts was significantly compromised. In fact, ∆EGFR lost all oncogenic 
potency with c-Met knockdown. These findings suggest that targeting c-Met in c-
Met-addicted GBMs that express the ∆EGFR, such as in a subset of tumors 
belonging to the mesenchymal GBM subgroup, may be an effective treatment 
strategy. However, very few mesenchymal GBMs were detected by Verhaak and 
colleagues (2010) to express the ∆EGFR. We predict that a large number of 
∆EGFR-expressing GBMs were not discovered in their study, due to the scanty 
expression of ∆EGFR in the bulk of a tumor that limits its detectability (Jungbluth 
et al., 2003; Wiesner et al., 2009), and due to TCGA’s sample exclusion criteria 
(Verhaak et al., 2010). Therefore, it is possible that the subset of mesenchymal 
GBMs that express ∆EGFR may be larger than reported by Verhaak et al. (2010). 
Using different techniques, other investigators have found that approximately 30% 
of GBMs contain the ∆EGFR mutation (Hwang et al., 2011), compared with the 
7% of GBMs reported by Verhaak et al. (2010).  
c-Met-dependent effectors of HGF expression that were identified in our 
phosphotyrosine-based mass spectrometry screen, mostly merged on STAT3.  
Others have found that HGF promoter activity is upregulated via STAT3 signaling 
in a variety of cancer cell lines (Tomida and Saito, 2004; Wojcik et al., 2006). 
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Interestingly, STAT3 expression is critical for maintenance of the mesenchymal 
gene expression signature, and of the associated aggressive phenotype of GBM 
(Carro et al., 2010). In agreement, aberrant STAT3 activity correlates with a poor 
survival prognosis for GBM patients (Birner et al., 2010). Zhang et al. (2002) 
provided evidence to suggest that STAT3 is a crucial component of the c-Met 
signal in cancer cells, which is required for anchorage-independent colony 
formation and tumor growth. We found that STAT3 activity was attenuated with c-
Met knockdown in U87 ∆EGFR cells, and that the loss in anchorage-independent 
growth of these cells could partially be restored via constitutively active STAT3 
expression. These data suggested that c-Met-mediated STAT3 signaling plays a 
key role in maintaining anchorage-independent growth of U87 cells expressing 
∆EGFR. 
It has been suggested that STAT3 Y705 phosphorylation is not significantly 
enhanced by ∆EGFR in GBM cells (Huang et al., 2009). However, the STAT3 
signal is recruited by ∆EGFR to induce the transformation of astrocytes (de la 
Iglesia et al., 2008). Additionally, proliferation and survival mechanisms 
associated with ∆EGFR expression in GBM cells are strengthened by STAT3 
signaling (Huang et al., 2009). We found that activated STAT3 partially modulates 
HGF expression in U87 ∆EGFR-expressing cells. It is possible that HGF-
stimulated c-Met activates STAT3 within the perinuclear compartment of U87 and 
U87 ∆EGFR cells, as this mechanism of compartmentalization of c-Met-
dependent STAT3 activation has been employed by other cancer cells 
(Kermorgant et al., 2008). Taken together, these data suggest that ∆EGFR usurps 
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the c-Met-dependent STAT3 signal in U87 cells, to partly promote oncogenicity via 
increased HGF expression.  
STAT3 signaling was necessary, yet insufficient, to modulate HGF 
expression in U87 cells, and in U87 cells expressing ∆EGFR.  Using IPA, we 
showed that C/EBPβ and STAT3 share upstream signaling molecules that 
regulate HGF expression in U87 and U87 ∆EGFR-expressing cells in a c-Met-
dependent manner.  Similarly to STAT3, C/EBPβ is a master regulator of the 
mesenchymal GBM subtype (Carro et al., 2010). These data suggest that 
activation of the C/EBPβ pathway will most likely be required, in addition to 
STAT3 signaling, in order to maximally upregulate the expression of HGF in c-
Met-dependent GBM cells.   
In summary, our data have highlighted the significant contribution of 
dysregulated c-Met pathway signaling, and of c-Met and ∆EGFR crosstalk, to 
GBM tumorigenesis. We have identified a new element in this network, the 
positive feedback on HGF expression by c-Met signaling, and connected it to the 
already known signal coming from ∆EGFR to c-Met. Our data show that this is an 
important component of the network for tumorigenesis, and by implication may 
represent an opportunity for therapy of tumors where these signals are important, 
the mesenchymal GBMs.  
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